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ABSTRACT 
Dengue virus (DENV) causes over 500,000 infections annually with a spectrum 
of clinical diseases ranging from subclinical infection to dengue, a mild febrile illness, to 
life-threatening severe dengue. Vascular leakage without endothelial cell damage is the 
hallmark symptom of severe dengue illness and is proposed to be directly mediated by 
soluble inflammatory mediators IL-8 and TNFα. IL-8 production occurs in response to 
DENV infection, is elevated during severe dengue, is proposed to inhibit interferon, and 
could potentially recruit target cells to sites of infection. We previously showed that 
expression of DENV NS5 activates the IL-8 promoter, induces IL-8 transcription, and 
induces IL-8 protein production in HepG2 and HEK293A cell lines. As multiple DENV 
proteins are reported to interact with important signaling pathways, we hypothesized that 
other DENV proteins could contribute to the activation of IL-8.  We found that plasmids 
expressing prM-E together, the GPI-linked variant of NS1 (NS1G), the carboxyl-terminal 
112 amino acids of NS4B, as well as NS5 each induced expression from an IL-8 
promoter-driven reporter plasmid.  Expression of NS5 also induced activation of a 
RANTES promoter construct and TNFα mRNA expression. Further, we found that the 
carboxyl-terminal polymerase domain of NS5 was sufficient to induce IL-8 secretion but 
polymerase function was not required. Like NS5, prM-E and NS1G induced luciferase 
expression from an AP-1-driven reporter plasmid. We further tested whether activation of 
the IL-8 promoter depended on any single transcription factor within IL-8 using IL-8 
promoter-driven plasmids mutated at the AP-1, C/EBP or NF-κB binding sites. We found 
that activation of the IL-8 promoter by prM-E, NS1G and NS4B did not depend on 
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activation of any single transcription factor. Our data suggested that AP-1 may be both 
positively and negatively inducing transcription, fitting with previous theories that DENV 
regulates IL-8 induction. However, we did not observe any differences in activation of 
AP-1 subunit c-Jun, or the inhibitory subunits Fra-1 or Fra-2 between DENV and mock-
infected cells. These data support a model in which multiple DENV proteins activate the 
IL-8 promoter, provide a potential basis of IL-8 induction by DENV in multiple cell 
types, and further supports a mechanism by which DENV contributes to severe dengue 
illness. 
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PREFACE 
Portions of this text and figures have been and may be prepared for separate 
publication. 
Figure I-2 is original, by the author. Figure I-1 was adapted from Lindenbach et 
al., 2007. Figure I-3 is partially adapted and based on Rothman, 2003 with author 
permission. Figure I-4 and Figure IV-1 are based on Hoffmann et al., 2002. Where 
adapted from copyright works, citations have been noted and additional information not 
included in the original figure has been added. 
Table I-1 was adapted from WHO and TDR, 2009. Table I-2  is derived from 
Pubmed Gene and Janeway et al., 2001. 
In Figure III-7, NS1-eGFP and NS1G-eGFP expression data was generated by 
Mr. Justin Deveau and Mr. Myles Walsh under the guidance and supervision of the 
author and has been presented by Mr. Deveau and Mr. Walsh as part of their Major 
Qualifying Project at Worcester Polytechnic Institute. Data analysis was performed by 
the author. All other data was generated and analyzed by the author as described. 
All primers listed in Table III-1 and Table III-4, with the exception of NS5-270C 
forward were designed by Carey Medin, Ph.D. Published primers are cited under Table 
III-1. Table III-2 is adapted from Polo et al., 1997 and includes sequencing data of the 
DENV-2 infectious clone from Polo et al., 1997 for comparison. All sequencing data of 
full length DENV protein inserts, prM-E, and NS1G was provided by Carey Medin Ph.D. 
Construction and sequencing of NS5-320 and NS5-368 was performed with Carey Medin 
Ph.D.  
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CHAPTER I: INTRODUCTION 
 
A. Dengue - Clinical background 
Over 2.5 billion people, approximately half of the world population, currently live 
in areas at risk of dengue virus (DENV) infection.  The World Health Organization 
(WHO) estimates that 50-100 million DENV infections occur every year.  Of those, an 
estimated 500,000 cases of severe dengue will require hospitalization and 2.5% of those 
affected will die.  Further, over 25,000 children die annually and DENV infection is a 
leading cause of childhood death in some Asian and Latin American countries (WHO and 
TDR, 2009; WHO, 2012).   
The Aedes aegypti mosquito is the most commonly associated vector for DENV 
transmission to humans, though other Aedes mosquitoes may also carry and transmit 
DENV (WHO, 2012).  The geographic distribution of Ae. aegypti and DENV is currently 
limited to tropical and subtropical regions worldwide, but through the Ae. albopictus 
mosquito, a secondary vector, DENV has the potential to spread further into more 
temperate regions (Lambrechts et al., 2010; WHO, 2012). As Ae. aegypti are day-biting 
mosquitoes, fewer precautions are taken during their peak activity, lending to disease 
transmission.  In addition, Ae. aegypti often reside in close contact with humans, 
reproducing in any available standing water.  Besides mosquitoes, humans are the only 
well-established natural hosts (WHO, 2012).   
The clinical presentation of DENV infection varies greatly. The WHO has 
recently reclassified DENV disease into three major classes: dengue, dengue with 
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warning signs, and severe dengue (WHO and TDR, 2009,Table I-1). DENV most often 
leads to subclinical infection or a relatively mild febrile illness with rash classified as 
dengue and similar to the previous classification of dengue fever (DF). Other symptoms 
and signs of dengue are nausea, vomiting, aches and pains, thrombocytopenia, and 
neutropenia. There are several more severe symptoms and signs that may manifest 
including abdominal pain or tenderness, persistent vomiting, fluid accumulation, mucosal 
bleeding, lethargy or restlessness, liver enlargement, and increase in hematocrit with 
concurrent decrease in platelet count. These symptoms are possible signs of severe 
dengue and their presence is classified as dengue with warning signs (WHO and TDR, 
2009; Srikiatkhachorn et al., 2011).  However, dengue may still progress to severe 
dengue without any prior manifestation of these warning signs. Severe dengue is 
diagnosed when one or more of the following symptoms and signs are present: severe 
plasma leakage leading to shock or fluid accumulation with respiratory distress, severe 
bleeding, liver involvement as defined by aspartate aminotransferase or alanine 
transaminase levels >= 1000 units per liter, central nervous system involvement as 
impaired consciousness, or the severe involvement of other organs. The previous 
classification of DENV infection differentiated a range of severe illness as dengue 
hemorrhagic fever (DHF) grades I-IV and dengue shock syndrome (DSS). The purpose 
of this new system is to clinically differentiate milder forms of dengue that do not require 
hospitalization from cases that may progress to more severe forms of dengue and require 
hospitalization. The old system is still used in many published studies. However, plasma 
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leakage due to vascular permeability without endothelial cell damage has been and 
continues to be the hallmark of both severe dengue and DHF.  
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Table I-1: WHO criteria for dengue diagnosis. 
Probable dengue Dengue warning signs Criteria for severe dengue 
Live in/travel to endemic 
area and 2 of the following 
Abdominal pain or 
tenderness 
Severe plasma leakage 
leading to: 
Nausea, vomiting Persistent vomiting Shock 
Rash Clinical fluid accumulation Fluid accumulation with 
respiratory distress 
Aches and pains Mucosal bleed  
Tourniquet test positive Lethargy, restlessness Severe bleeding 
Leukopenia Liver enlargement > 2 cm  
 Laboratory increase in HCT 
concurrent with rapid 
decrease in platelet count 
Severe organ involvement: 
Any warning sign  Liver AST or ALT >= 1000 
U/L 
  CNS: impaired 
consciousness 
Laboratory-confirmed 
dengue 
 Heart and other organs 
 
Adapted from WHO and TDR, 2009. 
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DENV is a composite of four closely related but antigenically distinct viruses 
referred to as serotypes (DENV1 – 4; Halstead, 1988). Primary infection with any one 
DENV leads to lifelong immunity to that serotype and transient immunity to the other 3 
serotypes (Sabin, 1952). When transient immunity wanes, secondary infection with a 
heterologous serotype may occur. While severe dengue can develop during primary 
infections, patients with secondary DENV infections have increased risk of developing 
DHF (Halstead et al., 1970) and presumably severe dengue. Tertiary and quaternary 
infections with DENV are also possible, however these have been difficult to document 
due to the predominantly subclinical or mild presentation of symptoms, limited efforts by 
clinicians to identify infecting serotypes during infection, and difficulty determining the 
number of previous DENV infections (van Panhuis et al., 2010; Endy et al., 2011). The 
increased risk of severe dengue during secondary infection complicates vaccine 
development strategies as an effective vaccine must produce protective immunity to all 
four serotypes. 
Currently, the most effective method of controlling DENV infection is by 
elimination of the mosquito vector.  Surveillance campaigns to eliminate domestic 
breeding grounds have been effective (Gubler, 1989).  However, these methods do not 
eliminate either the virus or the mosquito vector altogether, must be maintained annually, 
and even small changes to surveillance may result in increased disease transmission 
(Gubler, 1989; Ooi et al., 2006).  Increased DENV outbreaks are well documented when 
control measures have ceased (Ooi et al., 2006).  As much of the disease burden is on 
third world countries, there is often limited funding to maintain control efforts. 
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DENV infections carry significant socio-economic impact.  The burden of care 
and the expense of vector control is only part of this impact. There are also work days 
lost for patients and caregivers, expenses associated with the intensive care of severely 
infected patients, and the costs of disease surveillance. All of these expenses would be 
relieved by a vaccine (WHO and TDR, 2009). However, while significant progress 
towards a vaccine has been made in recent decades, including the development of several 
vaccine candidates, our limited knowledge of the mechanisms of disease progression 
remains an impediment. 
B. Dengue virus, replication, and structure 
DENV is a member of the family Flaviviridae and part of the flavivirus genus, 
which contains numerous viruses of human clinical importance (Reviewed in Lindenbach 
et al., 2007).  Related mosquito-transmitted flaviviruses are Yellow fever virus (YFV), 
members of the Japanese encephalitis (JE) virus group including St. Louis encephalitis 
virus, Murray Valley encephalitis virus, West Nile virus (WNV), and Kunjin virus 
(KUNV), Aroa virus, Kokobera virus, and Zika virus. DENV is also related to the tick-
borne flaviviruses Tick-borne encephalitis virus (TBEV), Alkhurma virus, and Langat 
virus. Within the family Flaviviridae, DENV is also related to hepatitis C virus (HCV).  
These viruses are all positive sense, single stranded, non-segmented RNA viruses 
encoding at least ten proteins: three structural and seven nonstructural proteins. 
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Figure I-1: DENV genome. 
The DENV vRNA has a 5’ CAP, lacks a poly-A tail and contains 5’ and 3’ UTRs. The 
DENV vRNA transcribes a poly-protein that is co- and post-translationally cleaved into 
ten viral proteins: three structural and seven NS proteins. In addition, prM is later cleaved 
to M, NS4A and NS4B are cooperatively cleaved from the 2K sequence, and NS1 has an 
alternative carboxyl-terminal cleavage site 26 aa within NS2A leading to the GPI-linked 
NS1G. Figure adapted from (Lindenbach et al., 2007).  
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The DENV virion contains three structural proteins.  The envelope (E) and 
membrane (M) proteins cover the membrane surface while the capsid (C) associates with 
the viral RNA inside the virion. E binds to one or more receptors including heparan 
sulfate proteoglycans (Dalrymple and Mackow, 2011) and lectins initiating receptor-
mediated endocytosis (reviewed in Hidari and Suzuki, 2011). Neolactotetraosylceramide, 
a glycosphingolipid, has been characterized as a possible coreceptor and a variety of 
other proteins have been proposed as additionally mediating uptake of one or more 
DENVs (Hidari and Suzuki, 2011). The lectin dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) is probably the best characterized 
DENV receptor, mediating entry into dendritic cells (DCs), one of the presumed primary 
targets of infection (Navarro-Sanchez et al., 2003; Tassaneetrithep et al., 2003). Upon 
lysosome fusion with the late endosome and subsequent acidification, E mediates pH-
dependent membrane fusion releasing the viral genome into the cytosol. 
The flaviviral RNA genome (vRNA) is capped, lacks a poly-adenosine tail, and is 
immediately translated by host cellular translation machinery upon initial release 
(Reviewed in Lindenbach et al., 2007; Figure I-1).  Translation produces a polyprotein 
that is co- and post-translationally cleaved by both host and viral proteases to yield all ten 
viral proteins.  Structural proteins are amino terminal in the order C, pre-membrane (prM, 
later cleaved to M) and E, followed by the seven non-structural (NS) proteins: NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5 (Figure I-1). 
All NS proteins are thought to play a role in vRNA replication.  NS3 contains 
enzymatic functions of both the viral protease, in association with NS2B, and the viral 
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helicase.  NS5 is the viral polymerase and also contains an amino-terminal 
methyltransferase domain involved in RNA capping. Viral replication is associated with 
invaginated endoplasmic reticulum (ER) membrane described as vesicle packets (Uchil 
and Satchidanandam, 2003).  These vesicle packets are peri-nuclear but it is unclear how 
vRNA associates with the replication machinery after initial translation. In the absence of 
a poly-adenosine tail, elements of the UTRs mediate circularization of the vRNA genome 
for replication (Gebhard et al., 2011). New vRNA is produced through a negative strand 
intermediate but RNA replication is asymmetric as vastly more positive strand vRNA is 
produced over the negative strand intermediate. New vRNA may either be translated or 
chaperoned by C for packaging by prM and E in new virions in ER-derived membranes 
(Pong et al., 2011). These immature virions transit through the golgi apparatus and 
mature within the golgi apparatus by cleavage of prM to M by the host protease furin 
(Stadler et al., 1997). Mature virus is then released into the extracellular space by 
exocytosis. 
Substantial progress has been made over the last decade elucidating both the 
structure and function of DENV proteins. Many viral proteins serve multiple roles, 
depending on factors such as cellular localization, association and interaction with 
cellular and viral proteins, and cell type (Reviewed in Lindenbach et al., 2007).  
However, much of this data is exclusively from cell culture models.  The contribution of 
each of these functions during human infection remains to be seen.  In addition, the 
functional nature of each DENV protein in mosquito infection remains poorly 
understood. 
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Capsid Protein 
DENV-2 strain New Guinea C (NGC) C protein is encoded by 339 nucleotides 
(nt), is 113 amino acids (aa) long, and is approximately 11 kilodaltons (kD) in size. C is 
initially processed into an immature form that contains a carboxy-terminal hydrophobic 
anchor.  This anchor signals appropriate translocation of prM into the ER prior to being 
cleaved from mature C by the NS2B-NS3 protease (Lobigs, 1993; Amberg et al., 1994). 
Flavivirus C proteins have been observed as dimers (Jones et al., 2003) and DENV C was 
determined to also be a dimer (Ma et al., 2004).  DENV C contains RNA chaperone 
activity while RNA binding proteins NS3 and NS5 do not (Pong et al., 2011).  Several 
flavivirus C proteins tolerate substantial truncation while still functioning in formation of 
the virion and packaging new virus (Kofler et al., 2002, 2003; Patkar et al., 2007; Schlick 
et al., 2009).  The C protein also localizes to the nucleus through multiple nuclear 
localization signals (Tadano et al., 1989; Mori et al., 2005; Sangiambut et al., 2008).  
It is still unclear exactly how and why C functions in the nucleus. However, C 
interacts with several cell signaling pathways. C sensitizes liver cells to Fas-dependent 
apoptosis through interaction with human death domain-associated protein Daxx 
(Limjindaporn et al., 2007; Netsawang et al., 2010).  Through Daxx, C activates JNK-
dependent signaling (Yang et al., 1997). C induces apoptosis of liver cells through 
interaction with cyclophilin binding ligand (CAML) and activation of Caspase-3 (Li et 
al., 2012).  C also modulates nuclear signaling pathways by binding histones and acting 
as a histone mimic (Colpitts et al., 2011). Similarly, C was also associated with induction 
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of IL-8 mRNA through direct promoter binding and recruitment of positive transcription 
elongation factor b (P-TEFb; Li et al., 2010). 
A major role for C during human infection appears to involve ER-derived 
organelles called lipid droplets (LDs).  C functions to increase lipid metabolism and LD 
formation (Samsa et al., 2009).  C then accumulates in LDs in a mechanism dependent on 
potassium ions (Carvalho et al., 2011) and the amino terminus of C (Martins et al., 2012; 
Samsa et al., 2012).  However, this function was dispensable for replication in mosquito 
cells (Samsa et al., 2012) indicating an organism-specific replication mechanism and C 
has yet to be associated with DENV-induced LD processing by autophagy (Heaton and 
Randall, 2011). 
Pre-membrane and Membrane Protein 
Following C anchor cleavage from mature C, the amino terminus of prM is 
produced by host signalase cleavage from C anchor (Amberg et al., 1994). The prM 
protein of DENV-2 NGC is encoded by 498 nt, consists of 166 aa, and is approximately 
26 kD in size.  The amino terminal 91 aa constitutes the pr segment. prM is cleaved to M 
by the host cell enzyme furin during transport through the golgi (Stadler et al., 1997).  
Cleavage of prM primes the virus for fusion upon acidification in the new host cell 
endosome. It has been noted that cleavage of prM is inefficient, leading to release of a 
substantial number of immature viral particles unable to infect new cells via receptor-
mediated uptake (Dejnirattisai et al., 2010).  However, these immature viruses can be 
bound by prM specific antibody and antibody-virus complex can induce uptake into and 
infection of cells bearing the Fcγ receptor (Dejnirattisai et al., 2010). M also contains a 9 
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carboxy-terminal aa pro-apoptotic peptide referred to as ApoptoM (Catteau, Kalinina, et 
al., 2003; Catteau, Roué, et al., 2003).  Apoptosis was dependent on golgi export of M to 
the cell surface and caspase activation (Catteau, Kalinina, et al., 2003). 
Envelope Protein 
E is encoded by 1,485 nt, 495 aa long, approximately 53 kD in size, and the 
immunodominant target for antibodies during DENV infection (Murphy and Whitehead, 
2011). DENV E contains at least 2 N-glycosylation sites, though glycosylation differs 
between virus serotypes (Johnson et al., 1994). While virus lacking both glycosylation 
sites or the glycosylation site at Asn-153 could not replicate in human cells, both viruses 
were viable in mosquito cells (Mondotte et al., 2007).  
Both neutral and low pH conformations of E in the virion have been observed by 
cryo-electron microscopy (Kuhn et al., 2002; Zhang et al., 2003). These structures 
demonstrate both the close packing of E dimers on outer membranes in a herringbone 
pattern in the virus at neutral pH as well as the dramatic conformational change to E 
trimers that occurs after exposure to low pH. 
Virus-like Particles and Replicons 
 In the absence of NS proteins and vRNA, prM and E of TBEV (Corver et al., 
2000; Ferlenghi et al., 2001; Allison et al., 2003; Lorenz et al., 2003) and DENV (Purdy 
and Chang, 2005; Hsieh et al., 2008; Shang et al., 2012) have been shown to form empty 
virus-like particles (VLPs) that are secreted into the culture supernatant. Expression of 
VLPs occurs most efficiently when prM and E are expressed together from the same 
13 
 
expression construct, in cis, as prM-E, but inefficiently when expressed from two 
separate expression constructs, in trans, as prM and E (Kuhn et al., 2002; Shang et al., 
2012). Formation and secretion of VLPs have been shown to be more efficient when C is 
also expressed in cis as C-prM-E in KUNV (Khromykh, Varnavski, et al., 1998). While it 
has yet to formally be shown that a C-prM-E expression construct is more efficient at 
DENV VLP formation, one study has demonstrated DENV particle formation to be 
drastically more efficient with the amino-terminus of C (Samsa et al., 2012). 
VLPs have also been shown to package vRNA-like genomes (Khromykh, 
Varnavski, et al., 1998; Gehrke et al., 2003) with deletions of the structural genes prM, E, 
and sometimes C (Pang, Zhang, and Dayton, 2001a, 2001b; Rossi et al., 2005). Replicons 
derive their name because they are RNAs that contain all the NS proteins and the UTRs 
required for continued self-replication, without production of new viral particles. 
Packaged replicons are produced in packaging cell lines that express the required 
structural genes from a separate expression construct (Khromykh, Varnavski, et al., 1998) 
and are a useful tool to study single cycles of infection and replication in the absence of 
packaging new virus. 
Replicons have been used extensively to study HCV, where the delay establishing 
a system for propagating virus forced researchers to utilize means other than direct 
infection to study viral replication (Lohmann et al., 1999; Mottola et al., 2002; Ali et al., 
2004; Ali and Kukolj, 2005; Taylor et al., 2005; Wilson and Richardson, 2005). 
Flavivirus replicons have been used to study vRNA replication (Khromykh, Varnavski, et 
al., 1998), test the requirements of specific viral proteins to be expressed from within the 
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polyprotein versus supplemented in trans (Khromykh, Kenney, et al., 1998), identify 
adaptive mutations (Rossi et al., 2005, 2007; Alcaraz-Estrada et al., 2010), identify 
cellular antiviral responses (Liu et al., 2004; Rossi et al., 2005; Hershkovitz et al., 2008), 
express heterologous proteins for vaccine potential (Pang, Zhang, and Dayton, 2001b), 
and test potential replication inhibitors (Hsu et al., 2012). Thus replicons are excellent 
tools to study viral and cellular processes in the absence of new virus production. 
In addition to replicons, expression of individual proteins has further elucidated 
the structures as well as additional roles of each NS protein during DENV infection. The 
following summarizes physical features of each protein, the major role in viral infection, 
and what is known about the role of each protein in signaling. 
Non-structural protein 1 
NS1 is encoded by 1056 nt, is 352 aa long, and 40 kD in size. The major function 
of NS1 is largely unknown, though it has been shown to play a role in viral replication 
(Mackenzie et al., 1996; Lindenbach and Rice, 1997; Westaway et al., 1997). NS1 is the 
only DENV NS protein that is secreted from the cell and contains two glycosylation sites 
(Blitvich et al., 1999). Intra-cellular NS1 exists as a homodimer, while extra-cellular NS1 
can be found either associated with the outside of infected and uninfected cells, as a 
soluble dimer, or as a hexamer in circulation. Currently, several assays are available to 
detect NS1 as a clinical diagnostic for DENV infection (Blacksell et al., 2012).   
 NS1 has been implicated in several clinically relevant roles. NS1 itself may 
mediate disruption of the endothelium through disruption of lipid metabolism (Gutsche et 
al., 2011). Yet DENV NS1 has also been implicated in direct mediation of complement 
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activation through the classical and lectin binding pathways. By direct binding of C4 and 
C1s, NS1 promotes cleavage of C4 to C4b. In addition, NS1 binds C4b binding protein 
(C4BP) which in turn inactivates C4b (Avirutnan et al., 2010, 2011). Other signaling 
pathways NS1 has been shown to directly interact with include signaling through 
STAT3β and induction of IL-6 and tumor necrosis factor α (TNFα) (Chua et al., 2005). 
As a secreted protein, NS1 is one of the major antigenic targets during infection. 
Antibodies to NS1 may mediate lysis of endothelial cells through nitric oxide production 
(Lin et al., 2002). In addition, antibodies to NS1 have been shown to enhance NS1-
mediated complement activation (Avirutnan et al., 2006). Therefore, antibodies to NS1 
have been proposed to be a risk factor for severe dengue. 
 Studies have demonstrated that membrane-anchored NS1 is a second form 
produced during infection by alternate cleavage of the carboxy-terminal end (Jacobs et 
al., 2000; Silva et al., 2011).  This produces a form of NS1 that contains 26 aa of NS2A 
and an attachment site for a glycosylphospho-inositol (GPI) linkage. In this work, we 
designate this GPI-linked form of NS1 as NS1G. Further, NS1G has been shown to 
mediate signaling after antibody binding (Jacobs et al., 2000; Silva et al., 2011) and 
associate with lipid rafts (Noisakran et al., 2008). The exact role of this cell surface 
signaling during DENV infection remains to be determined. 
 DENV is not the only flavivirus to produce an alternate form of NS1. Both JEV 
and WNV of the JE serogroup have been shown to produce NS1’ through ribosomal 
frameshifting -1 nt leading to the addition of 52 aa from nucleotide sequence within the 
NS2A coding region (Firth and Atkins, 2009; Melian et al., 2010). Specifically, the 
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ribosomal frameshift is dependent on a pseudoknot structure within the NS2A coding 
region. Mutations in the pseudoknot that abrogate NS1’ production led to increased JEV 
production (Winkelmann et al., 2011). However, mutations that abrogate the pseudoknot 
in KUNV had no effect on replication, but decreased the neuroinvasiveness of the virus 
(Melian et al., 2010). Thus, DENV and viruses of the JEV serogroup have evolved 
distinct forms and functions for alternative forms of NS1. 
Non-structural proteins 2A and 2B 
NS2A and NS2B are small viral proteins with no known enzymatic function of 
their own. NS2A is encoded by 654 nt, is 218 aa long, and 24 kD in size. The amino-
terminus of NS2A is produced by host ER protease cleavage requiring the 8 carboxyl-
terminal aa of NS1 (Hori and Lai, 1990). NS2A has been shown to interfere with IFN-β 
signaling (Muñoz-Jordan et al., 2003), though the mechanism is not known. 
NS2B is encoded by 390 nt, is 130 aa long and 14 kD in size. NS2B is a required 
cofactor for NS3-mediated protease function. The hydrophilic 40 aa NS3 protease 
cofactor domain is located from residues 45 – 95 (Leung et al., 2001). Recently, NS2B in 
its entirety has been characterized by NMR (Huang et al., 2011). Both the amino- and 
carboxyl-termini are produced by viral protease cleavage within the cytosol (Preugschat 
et al., 1990). NS2B has not been characterized to interact with any known signaling 
pathways. 
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Non-structural protein 3 
NS3 is encoded by 1854 nt, is 618 aa long, and 69 kD in size. Both the amino- 
and carboxyl-terminal ends are cleaved from the rest of the polyprotein by the NS2B-
NS3 protease. NS3 protein contains serine protease, helicase, RNA-stimulated nucleoside 
triphosphatase (NTPase), and RNA triphosphatase (RTPase) enzymatic functions. The 
amino-terminal 1-180 aa contain the protease domain. As previously mentioned, protease 
function requires the cofactor NS2B. The helicase and triphosphatases in the carboxyl-
terminal 180 – 618 aa (Xu et al., 2005) are integral to viral replication (Reviewed in 
Lindenbach et al., 2007; Perera and Kuhn, 2008). 
 While DENV NS3 has no known function in signaling, WNV NS3 has been 
shown to induce apoptosis in the mouse neuroblastoma cell line Neuro-2a and the human 
muscle cell line RD (Ramanathan et al., 2006). Apoptosis could be prevented with 
inhibitors of caspase-3 or caspase-8 and could be induced with either the protease or 
helicase domains, but was more efficient with the protease domain. Thus, DENV NS3 
may yet have an uncharacterized role in signal transduction. 
Non-structural protein 4A 
Mature NS4A is encoded by 381 nt, is 127 aa long, and 14 kD in size and one of 
the least characterized DENV proteins. NS4A exists as an integral membrane protein 
with four putative transmembrane domains (pTMDs), the last of which is the 2K 
sequence. The amino terminus of NS4A is generated by NS2B-NS3-mediated cleavage 
from NS3 (Chambers et al., 1990; Lin, Chambers, et al., 1993). 
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While NS4A has no known specific function, it is required in both the DENV 
(Miller et al., 2007) and KUNV replication complexes, colocalizing with dsRNA 
(Mackenzie et al., 1998). Expression of NS4A lacking the 2K sequence was shown to 
induce ER membrane-derived punctate cytoplasmic structures reminiscent of the sites of 
viral replication (Miller et al., 2007) though based on studies in KUNV, this may be 
enhanced in the presence of NS4A-2K-NS4B in the polyprotein precursor (Roosendaal et 
al., 2006).  
NS4A has been implicated in two very diverse signaling pathways. Like NS2A 
and NS4B (below), NS4A was shown to inhibit the type I IFN response (Muñoz-Jordan 
et al., 2003). More recently, it was demonstrated that NS4A induced autophagy in a 
phosphoinositide-3-kinase (PI3K)-dependent manner (McLean et al., 2011). This 
induction of autophagy protected epithelial cells and fibroblasts from virus-induced cell 
death and inhibition of PI3K decreased virus production. The protective effect of 
autophagy was not observed in murine macrophages, consistent with another report that 
autophagy reduces DENV output in the monocytic U937 cell line (Panyasrivanit et al., 
2011). Thus, NS4A may be important in establishing longer term infection in epithelial 
cells. 
2K Sequence 
The 2K sequence is encoded by 69 nt, is 23 aa long, and 2 kD in size. The 2K 
sequence has no known function, but cleavage is required for appropriate function of 
NS4A and appropriate orientation and function of NS4B (Lin, Amberg, et al., 1993). 
Cleavage of the NS4A/2K site is by the viral protease, and has in most recent studies 
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been characterized as preceding cleavage of the 2K/NS4B interface by a host cellular 
protease (Preugschat and Strauss, 1991; Lin, Amberg, et al., 1993; Roosendaal et al., 
2006), though cleavage may be inefficient and regulation of this cleavage appears 
required for the invaginated membranes where DENV replication occurs (Roosendaal et 
al., 2006). 
Non-structural protein 4B 
NS4B is encoded by 744 nt, is 248 aa long, and 27 kD in size. While the structure of 
NS4B has yet to be definitively determined, five pTMDs have been predicted. The 
orientation of these pTMDs was tested experimentally through subcellular localization, 
membrane association, and mapping of the membrane associated topology (Miller et al., 
2006). From that data, a model has been generated indicating insertion of three major 
pTMDs while two additional pTMDs remain within the ER lumen. Further, a possible 
internal glycosylation site was predicted on pTMD2, though it was unclear by Western 
blotting whether there was a glycosylated form. 
NS4B has been characterized to interfere with the interferon pathway through 
inhibition of STAT1 (Muñoz-Jordan et al., 2003). However, cytoplasmic NS4B may play 
an additional role interfering with interferon production. The amino terminus of NS4B 
from both DENV and YFV were identified as having high homology to the amino-
terminus of the ER resident stimulator of interferon genes (STING). STING serves as an 
intermediate between the retinoic acid inducible gene-I (RIG-I), which recognizes 
cytoplasmic dsRNA and tank binding kinase-1 (TBK-1). TBK-1 activates IFN response 
factor-3 (IRF-3) which mediates transcription of IFN-β (Ishikawa and Barber, 2008). 
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YFV NS4B associated with STING and inhibited STING-induced IFN-β production 
(Ishikawa et al., 2009). Thus, NS4B may play multiple roles in suppressing type I IFN. 
 Finally, NS4B has recently been shown to induce IL-6, IL-8, IP-10, TNFα, and 
IFN-γ secretion from the monocytic THP-1 cell line (Kelley et al., 2011). However, this 
contrasts with previous data from our lab showing NS4B did not activate IL-8 secretion 
in HEK293 cells (Medin et al., 2005).  
Non-structural protein 5 
The last of the NS proteins, as well as the largest, is NS5, encoded by 2700 nt, is 
900 aa long and 100 kDa in size.  The structure of NS5 contains two major domains.  
Each domain of NS5 has been crystallized independently (Egloff et al., 2002; Yap et al., 
2007).  The amino-terminal third of the protein contains methyltransferase and 
guanylyltransferase enzymatic functions, essential for vRNA capping (Henderson et al., 
2011), while the remaining two thirds of NS5 contain the viral polymerase.  In addition, 
NS5 was initially characterized to contain two nuclear localization signals (NLSs) 
(Forwood et al., 1999; Johansson et al., 2001; Brooks et al., 2002) within the polymerase 
region (Yap et al., 2007). Only one, the aNLS at aa residues 369 – 389 binding importin 
α/β, was characterized as important to replication during DENV infection (Pryor et al., 
2007). The second, bNLS, is at aa residues 320 – 368, competitively binds importin β and 
NS3 (Johansson et al., 2001; Brooks et al., 2002) and includes a nuclear export sequence 
(NES) that binds exportin 1 (yeast homologue chromosome region maintenance 1; 
CRM1; Rawlinson et al., 2009). 
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Properties of NS5, including association with NS3 (Kapoor et al., 1995), 
methyltransferase function (Bhattacharya et al., 2009), and nuclear localization (Forwood 
et al., 1999) may be regulated by phosphorylation. Adjacent to the functional aNLS is 
phosphorylation site on threonine-395 that is a substrate of Casein Kinase 2 (CK2) 
(Forwood et al., 1999).  Phosphorylation of the methyltransferase of YFV is prevented by 
inhibition of the serine/threonine kinase CK1 and the conserved serine-56 is 
phosphorylated directly by CK1α (Bhattacharya et al., 2009). 
 In addition to its enzymatic role in viral replication, NS5 has additional roles in 
cell signaling. NS5 is well established to induce IL-8 transcription and secretion (Medin 
et al., 2005; Medin and Rothman, 2006; Pryor et al., 2007; Rawlinson et al., 2009).  
Secretion of IL-8 is dependent on NS5 nuclear export by the cellular protein CRM1 
(Rawlinson et al., 2009), but paradoxically, is increased when the NLSs in NS5 are non-
functional (Pryor et al., 2007). Non-functional NS5 NLSs also led to decreased viral 
replication, leading the authors to suggest that while cytoplasmic NS5 induces production 
of IL-8, nuclear NS5 inhibits induction of IL-8 to reduce potential antiviral effects (Koo 
et al., 2006). 
Like the NS2A, NS4A, and NS4B proteins, NS5 interferes with type I IFN 
signaling (Ashour et al., 2009). This was not entirely unexpected as NS5 from both 
TBEV and JEV also disrupt IFN signaling by interfering with Tyk2 signaling (Best et al., 
2005; Lin et al., 2006). However, characterization of DENV NS5 revealed that it 
mediates STAT2 binding and degradation, though degradation would only occur when 
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the amino-terminus of NS5 was produced by cleavage by the NS2B-NS3 protease 
(Ashour et al., 2009). 
 Infection with DENV has been noted to interfere with HIV replication, a property 
mediated by NS5 (McLinden et al., 2008).  In a CD4 T cell line, this interference appears 
to occur through induction of the chemokine SDF-1 (CXCL-12) and partially 
downregulation of the HIV coreceptor of CXCR4 (McLinden et al., 2008).  NS5 
interference with HIV replication correlates with a similar finding with a peptide within 
NS5A of the related GB virus C (Xiang et al., 2008) and may also explain similar HIV 
interference by NS5A from HCV and the NS5 from YFV and WNV (Xiang et al., 2009). 
 Lastly, NS5 RdRP activity was implicated to be the target of nitric oxide (NO)-
mediated inhibition of DENV replication (Takhampunya et al., 2006). Further, a 
comparative sequence analysis between 10 clinical isolates of DENV implicated NS5 as a 
determinant of NO susceptibility (Ubol, Chareonsirisuthigul, et al., 2008).  DENV strains 
resistant to the anti-viral effects of NO correlated with mutations within the 621 – 646 aa 
range of NS5. To identify this region, partial sequences of both the methyltransferase and 
polymerase domains from the NO susceptible and NO resistant clinical isolates were 
compared. NO resistance by specific DENV-2 genotypes associated with DHF correlated 
with increased NO secretion, and stimulation of IL-6, IL-8, and RANTES during 
infection of the monocytic THP-1 cell line. NO can induce IL-8. However, whether NS5 
alone induces NO has not been determined. 
 C, prM, NS1, NS2A, NS4A, NS4B, and NS5 have all been observed to interact 
with one or more significant signaling pathways that directly or indirectly induce 
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cytokine production. C and prM interact with apoptotic pathways while NS2A, NS4A, 
NS4B, and NS5 have all been shown to inhibit the interferon pathway. C and NS4A 
additionally regulate lipid metabolism. Further, C, NS4B, and NS5 have all been shown 
to induce IL-8, suggesting the induction, and possibly regulation of IL-8 production is 
integral to DENV infection.  
C. Cellular pathogenesis of DENV infection 
The question remains of how and why infection with one DENV can lead to more 
severe disease during secondary infection with a heterologous DENV.  Theories have 
been advanced that include antibody-dependent enhancement of infection (ADE) as well 
as cross-reactive memory T cell-mediated enhancement of cytokine production, both of 
which may lead to a dysregulation of cytokine secretion (Reviewed in Pang et al., 2007; 
Murphy and Whitehead, 2011; Rothman, 2011; Whitehorn and Simmons, 2011).  This 
massive induction of multiple cytokines, termed a “cytokine storm”, is most likely the 
key mediator of severe dengue. Cytokines associated with severe dengue include 
CXCL9, CXCL10, CXCL11, IFN-α, IFN-γ, IL-6, IL-8, IL-10, MIF, TNFα, and VEGF 
(reviewed in Rothman, 2011; Table I-2). The cytokine storm, as well as the phenomenon 
of enhanced disease during secondary infection, are both exclusively observed in human 
infections and have yet to be adequately reproduced within any animal system.  However, 
several tissue culture and animal models are currently used to study and evaluate DENV 
infection and host responses.   
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Cellular targets of DENV infection 
DENV infection targets and alters several immune cells, particular antigen 
presenting cells (APCs). Monocytes in general are infected by DENV.  Dendritic cells are 
thought to be a primary target of DENV infection and Langerhans cells are thought to be 
the primary target on initial infection following a mosquito bite (Wu et al., 2000; Limon-
Flores et al., 2005; Lozach et al., 2005). However, keratinocytes have also been shown to 
be infected on initial inoculation (Limon-Flores et al., 2005; Surasombatpattana et al., 
2011). Infection of keratinocytes may be enhanced by mosquito saliva 
(Surasombatpattana et al., 2012). Other APCs such as macrophages (Halstead and 
O’Rourke, 1977) and mast cells (King et al., 2000) have also been implicated as key 
targets of infection and are probably initially infected on migration to the site of 
infection. DENV infection of DCs induces maturation (Libraty et al., 2001) and 
migration to lymph nodes may aid dissemination of virus to the rest of the body.  Many 
cells may be infected on viral dissemination. Hepatic cells have been shown to be 
infected (Lin et al., 2000) and, while liver involvement is a symptom of severe dengue 
and DHF, the importance of that involvement to the overall pathogenesis has yet to be 
clarified.  Direct infection of endothelial cells may also play a role. However there are 
conflicting reports as to the levels of infection of primary human endothelial cells in vitro 
(Avirutnan et al., 1998; Dalrymple and Mackow, 2011). 
High levels of pro-inflammatory cytokines are observed during DF, but are higher 
in DHF and thought to be the key mediators of the pathogenesis of severe disease (Pang 
et al., 2007; Rothman, 2011). DENV infected APCs are thought to influence dengue 
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pathogenesis by directly increasing the production of pro-inflammatory cytokines. 
Therefore, a number of studies have characterized cytokine production by DENV 
infected APCs (Figure I-2, Table I-2). Tumor necrosis factor (TNFα) is well 
characterized as being elevated in DHF versus DF and produced early in all infected 
APCs (Ho et al., 2001; Libraty et al., 2001; Chen and Wang, 2002; Espina et al., 2003; 
Dejnirattisai et al., 2008).  Similarly, IL-6 (King et al., 2000; Kamau et al., 2009) and IL-
8 (King et al., 2000; Chen and Wang, 2002; Kamau et al., 2009) have both been observed 
to be produced in culture from infected APCs.  DENV-infected dendritic cells, 
macrophages, and monocytes produce interferon-α (IFNα; Ho et al., 2001; Libraty et al., 
2001; Chen and Wang, 2002; Kamau et al., 2009). Infected dendritic cells and 
macrophages produce IL-12 (Libraty et al., 2001; Chen and Wang, 2002).  DENV-
infected macrophages and mast cells produce IL-1β (King et al., 2000; Chen and Wang, 
2002). Infected macrophages and monocytes also produce the chemokines RANTES 
(CCL-5), and MIP-1α (CCL-3).  Infected dendritic cells also produce interferon-γ (IFN-γ) 
and the chemokines Mig (CXCL-9), IP-10 (CXCL-10), and I-TAC (CXCL-11) 
(Dejnirattisai et al., 2008).  Therefore, higher viral load observed in severe dengue and 
DHF may at least in part explain why these cytokines are also increased. 
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Table I-2: Properties of soluble factors associated with severe dengue. 
Factor Secreting Cells Receptors Target cells Actions 
CXCL9 (Mig) IFNGR expressing CXCR3 Activated T cells Chemotaxis 
CXCL10 (IP-10) IFNGR expressing CXCR3 Activated T cells Chemotaxis 
CXCL11 (I-TAC) IFNGR expressing CXCR3 Activated T cells Chemotaxis 
IFN-α Leukocytes CD118, 
IFNAR2 
Most somatic cell 
types 
Antiviral, increased MHC 
class I expression 
IFN-γ T cells, NK cells CD119, 
IFNGR2 
Macrophages, 
monocytes, B cells, 
endothelium 
Macrophage activation, 
increased expression of MHC 
and antigen processing 
components, IG class 
switching, suppresses Th2 
IL-6 T-cells, 
macrophages, 
endothelial cells 
CD126, 
CD130 
Most cell types, 
activated B cells 
and plasma cells 
strongly responsive 
T and B cell growth and 
differentiation, acute phase 
protein production, fever 
IL-8 (CXCL-8) Endothelial cells, 
epithelial cells, 
macrophages, mast 
cells, NK cells, 
neutrophils 
CXCR1, 
CXCR2 
Macrophages, 
mast cells, NK cells,  
neutrophils, T cells 
Chemotaxis, endothelial cell 
permeability, negative 
regulation of type I IFN 
IL-10 T cells, 
macrophages 
IL-10Rα, 
IL-10Rβ 
B cells, T helper 
cells, 
macrophages, 
monocytes 
Suppression of macrophage 
function 
MIF T cells, pituitary 
cells 
CD74 B cells, 
Macrophages, 
monocytes 
Inhibits macrophage 
migration, stimulates 
macrophage activation, 
induces steroid resistance 
TNF (TNFα) Macrophages, NK 
cells, T cells 
TNFR1, 
TNFR2 
Most somatic cells, 
epithelial cells, 
myeloid cells 
Local inflammation, 
endothelial activation 
VEGF (VEGFA) Undefined VEGFR1, 
VEGFR2, 
VEGFR3 
Endothelial cells, 
epithelial cells, 
basophils 
Angiogenesis, anti-apoptosis, 
basophil and endothelial cell 
chemotaxis, cell maturation, 
epithelial cell differentiation, 
heparin binding, 
vasculogenesis, vascular 
permeability 
 
Information derived from Pubmed Gene and Janeway et al., 2001. 
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While monocytes and APCs are most likely the primary target of infection, other 
cell types that are thought to contribute to severe dengue have been examined in cell 
culture models. The two most studied are endothelial cells and liver cells, based on the 
symptoms of capillary leakage and liver involvement, respectively. 
Endothelial cells have a low level of infection in cell culture, but have been 
shown to secrete the clinically relevant cytokines IL-6 and IL-8 upon infection with 
DENV (Avirutnan et al., 1998; Huang et al., 2000). Further, the properties of endothelial 
cells change with the addition of other factors proposed to enhance dengue and including 
TNFα (Yen et al., 2008; Liu et al., 2009) and antibodies to NS1 (Lin et al., 2005). These 
changes included enhancement of cell permeability and increased secretion of IL-8 and 
IL-6. Moreover, infection of endothelial cells has been shown to enhance endothelial cell 
permeability, partially through the effects of IL-8 (Talavera et al., 2004).  However, at the 
onset of plasma leakage, virus has been cleared suggesting a minimal role for infection of 
endothelial cells by DENV during severe disease in vivo. 
Several disease-associated cytokines are secreted by hepatic cells following 
infection.  These include HMGB-1 (Higa et al., 2008), IFN-β, IL-6, IL-8, MIP-1β, and 
RANTES (Lin et al., 2000; Medin et al., 2005; Conceição et al., 2010). Signaling 
inducing production of these factors has also been examined, suggesting a wide range of 
activated pathways. Oxidative stress-induced C/EBP (Lin et al., 2000), innate sensors 
such as TLR3, TLR8, RIG-I, and MDA5 (Conceição et al., 2010), caspase-8 and caspase-
10 apoptotic pathways (Conceição et al., 2010), and NF-κB-induced apoptotic pathways 
(Marianneau et al., 1997) have all been demonstrated to activate cytokine production. 
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During DF, viremia peaks between days 1-3 of illness, the febrile phase, and 
symptoms during usually begin to wane during days 3-6. During DHF and severe dengue, 
days 3-6 are the critical phase, when organ impairment, bleeding, and shock manifest 
although by this time virus has been cleared from both serum and tissues. Days 6-10 are 
the recovery phase, when platelet counts return to normal and IgM and IgG become 
detectable (for primary infection).  
While the secretion of cytokines from DENV-infected cells plays a role in severe 
dengue and DHF, the clearance of virus during the early part of the critical stage 
emphasizes the immune-mediated nature of severe dengue. Many of the cytokines 
mentioned above further induce positive feedback loops of their own expression, in 
addition to inducing each other in larger positive feedback loops. This cascade of 
cytokine activation is the key feature of the cytokine storm model of DENV 
pathogenesis. 
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Figure I-2: Cytokine production by DENV infected cells. 
DENV infection of specific cell types are shown in order of possible relevance, with 
dendritic cells thought to be the primary target of infection. Infection of endothelial cells 
is shown as least important due to the lack of endothelial cell damage and because virus 
is cleared by the onset of vascular leakage. The actual order of importance is not known. 
Only cytokines that have been demonstrated to be induced during DENV infection are 
shown. 
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Proposed mechanisms of severe dengue 
Severe dengue occurs transiently after the febrile stage of infection with little 
vascular damage, which suggested that circulating factors primarily mediate severe 
dengue. As pro-inflammatory factors are elevated in DHF versus DF, associated with 
vascular leakage, and occur after peak viremia, it is thought that the cytokine storm is 
immune mediated (Reviewed in Rothman and Ennis, 1999). Along with infected cells, 
several other cell types are thought to play roles in creating the cytokine storm.  Both 
memory B cells through antibodies to previous DENV infection (Halstead et al., 1970; 
Halstead and O’Rourke, 1977) and memory T cells (Kurane and Ennis, 1992) have been 
proposed to be key regulators during a secondary infection. Both are likely to play roles 
in pathogenesis. 
The increased risk of severe disease during heterologous secondary infections 
suggested that an adaptive immune response is responsible for the pathogenesis of severe 
dengue.  The unusually high incidence of DHF in infants under one year of age during 
primary infection and the similarity to disease in older children with secondary infection 
(Halstead et al., 1970) led to the hypothesis that passive transfer of antibodies from 
mother to child could be increasing the early childhood risk of severe infection. In 
addition, it was postulated in adults that antibodies to a primary infection could be the 
adaptive response increasing the risk of severe disease in secondary infections. This 
hypothesis appeared further confirmed with the discovery that antibodies could enhance 
infection of macrophages, termed antibody-dependent enhancement of infection (ADE; 
Halstead and O’Rourke, 1977).  Dilution of anti-DENV neutralizing antibodies can 
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abrogate the neutralizing effect and lead to ADE.  Furthermore, it was confirmed that 
cross-reactive non-neutralizing antibodies to a primary infection could also mediate ADE 
to a heterologous serotype in vitro. More recent studies have questioned the role of ADE 
in infants and schoolchildren (Laoprasopwattana et al., 2005; Libraty et al., 2009). The 
first, a prospective study in a cohort of Thai schoolchildren, questioned whether DENV 
enhancing activity by antibodies in pre-illness plasma could correlate with clinical 
severity in secondary infection (Laoprasopwattana et al., 2005). The second, a 
prospective study in a cohort of Philippine infants directly tested whether maternally-
derived neutralizing or enhancing anti-DENV antibodies could be correlated with dengue 
severity at the time of infection (Libraty et al., 2009). Neither of these studies could 
correlate antibody activity with disease severity. This more recent data on ADE, as well 
as NS1 antibody-mediated enhancement of complement activation (above – see Non-
structural protein 1), collectively, indicate that, while antibodies may play a role, dengue 
pathogenesis is additionally mediated by other factors. 
Antibodies have additionally been implicated to mediate cellular immunity during 
secondary DENV infection. Natural killer (NK) cells are an important link between both 
adaptive and innate immunity. Along with the innate cytotoxicity for which they are 
named, NK cells function to prime CD8
+
 T cells, predominantly through secretion of 
IFN-γ in response to other pathogens (Vankayalapati et al., 2004) and may do the same 
during DENV infection. Primary NK cells were shown to mediate antibody-dependent 
cellular cytotoxicity (ADCC) or targeted lysis of infected cells (Kurane et al., 1984). 
CD16
+
 NK cells have not been shown to affect DENV replication in a tamarin model 
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(Yoshida et al., 2011), thus CD16
-
 cells presumably mediate ADCC. CD16
+
 NK cells 
may still contribute to cytokine production and cytokine storm during severe dengue in 
human infection (below).  It should be noted though that early activation of NK as well as 
NKT cells is associated with milder disease (Azeredo et al., 2006; St John et al., 2011). 
However, the mixed roles of antibodies and NK cells highlight the complex nature of 
dengue pathogenesis. 
 T cells may play an equally complex role during DENV infection that is still not 
well understood (reviewed in Pang et al., 2007; Mathew and Rothman, 2008; Murphy and 
Whitehead, 2011; Rothman, 2011; Whitehorn and Simmons, 2011). Like antibodies, T 
cells may also enhance cytokine secretion and the risk of cytokine storm during 
secondary DENV infection.  Following primary infection, patients generate a repertoire 
of memory T cells specific to the primary infection.  During secondary infection with a 
heterologous DENV serotype, memory T cells with lower avidity and less specificity for 
the infecting virus are preferentially activated over naïve T cells with greater specificity 
and higher avidity. Instead of mediating protection, these memory T cells are less 
effective at clearing infection. This was demonstrated in CD8
+
 T cells from Thai 
schoolchildren experiencing acute secondary DENV infection (Mongkolsapaya et al., 
2003). CD8
+
 T cells during acute secondary infection showed low affinity to the infecting 
virus, impaired IFNγ response, and were apoptotic. This preferential activation of low 
avidity T cells is thought to be due to the phenomenon of “original antigenic sin”, where 
a specific reaction to one virus may mediate a less specific reaction to a subsequent 
infection with a second, similar virus (Welsh and Rothman, 2003).  In this context, 
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memory T cells, instead of mediating protection, secrete more immune activating 
cytokines. This early, enhanced cytokine production further activates cytokine-mediated 
signaling cascades, leading to the cytokine storm, severe dengue, and the characteristic 
vascular leakage without endothelial cell damage. 
 Thus, a complete model of DENV pathogenesis can be built from all of these 
theories (Figure I-3). ADE increases the uptake of a secondary, heterologous DENV in 
Fcγ receptor-containing cells, increasing viral replication, DENV titers, and contributing 
to secretion of cytokines such as type I IFNs, IL-6, IL-8, and TNFα. Antibody to NS1 
enhances NS1-mediated complement activation as well as secretion of TNFα. E 
activation of NKp44 could contribute to CD16
-
 NK cells mediating protection through 
ADCC during secondary infection, a phenomenon that also correlates with the early 
protective response of IFNγ. Also during heterologous secondary infection, early 
activation of cross-reactive memory T cells that cannot mediate protection correlates with 
increased IL-2 and late expression of IFNγ as well as further enhancement of cytokine 
secretion. While additional cytokines likely contribute, IL-8 and TNFα are sufficient to 
mediate vascular endothelial cell permeability without cell damage, the hallmark of DHF. 
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Figure I-3: Model of DENV infection. 
DENV infection begins with infection of Langerhans DCs and basal keratinocytes in the 
tissues, initiating cytokine production. During primary infection, direct entry of DENV 
into target cells and NS1-mediated compliment activation are the primary means of 
DENV-mediated cytokine production. Cytokine production may lead to a positive 
feedback loop and cytokine storm, mediating vascular endothelial cell permeability and 
plasma leakage without vascular endothelial cell damage, the hallmark of severe dengue. 
During secondary infection with a heterologous DENV serotype, there is increased risk 
of severe dengue. Cytokine production is enhanced in the presence of DENV-specific 
non-neutralizing antibodies, presumably through ADE. ADE is mediated by DENV-
specific non-neutralizing antibodies, increases uptake of virus and infection of FcγR 
containing cells, and leads to increased DENV load. Antibodies to NS1 cross react with 
endothelial cells through molecular mimicry, further enhancing cytokine production. In 
addition, cross-reactive memory T lymphocytes to a primary infection can increase 
cytokine production during secondary infection instead of mediating protection. Early 
activation of NK cells is associated with decreased incidence of severe dengue, possibly 
through the mechanism of ADCC. However, activation of NK cells may also be 
contributing enhanced cytokine production during secondary infection. Figure is based on 
and partially adapted from Rothman, 2003.  
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Experimental Models of DENV Infection 
Many lab models are currently used in DENV research and range from animal to 
cell culture models. In general, animal models have failed to recapitulate the symptoms 
of severe dengue, as recently reviewed extensively (Zompi and Harris, 2012). However, 
certain models provide intriguing insights into the nature of severe dengue. 
 Mouse models have been used extensively to study severe dengue. Mice in 
general do not show symptoms of dengue. Illness can be induced by intra-cranial 
inoculation with a high viral titer. However, illness from intra-cranial inoculation is not 
representative of dengue in humans. Mouse-adapted strains of DENV have also been 
used. While these two models do show illness, they do not necessarily show disease that 
parallels human illness. Humanized mice have shown some promise in mirroring the 
immune response, yet the reconstitution of individual mice leads to extensive variation in 
results. A recent mouse model of infection suggests that tissue damage in general, and 
liver damage specifically, may be a key mediator of shock during severe dengue (Cheung 
et al., 2011). This model used a sublethal dose of concanavalin A to induce liver damage 
and sensitize C57BL/6 mice to DENV-induced shock. The resulting shock was dependent 
on liver infiltration with myeloid-DAP12-associating lectin-1 (MDL-1)-expressing cells 
with a neutrophil-like phenotype. Shock could also be triggered in the absence of DENV 
with an antibody stimulating MDL-1. Another model in AG129 mice, a mouse strain that 
lacks receptors for IFNα, -β, and -γ, comes even closer to recapitulating human disease 
(Tan et al., 2010). Intraperitoneal inoculation of AG129 mice with a low dose of DENV-
2 strain D2Y98P showed viral dissemination and replication in liver, spleen, and brain. 
36 
 
Peak viremia in this model was 6 days post infection prior to death a few days following 
viral clearance. In addition, animals showed signs of vascular permeability without cell 
damage following viral clearance, though the authors observed that animals died of 
another, unknown cause. 
 Non-human primates have been reported as permissive to DENV infection, and 
develop transient viremia, but do not show clinical symptoms. This model has been used 
to examine vaccine and anti-viral responses. Recently another non-human primate model 
has been described (Onlamoon et al., 2010). This model involves high titer (10
7
 PFU/mL) 
intravenous inoculation of rhesus macaques with DENV-2 strain 16681, the rationale 
being to recapitulate the high viral titer observed during severe dengue in humans. 
Subjects develop what the authors described as classic dengue hemorrhage with vascular 
endothelium damage. While further validation is required, like all non-human primate 
studies, this model suffers from the drawback of expense. 
 In vitro studies utilizing primary human cells have taken two approaches. One is 
to infect naïve donor cells before or after culture and study the subsequent responses. The 
second is to study dengue patient samples prior to, during, and after infection in 
prospective clinical studies. Both approaches have yielded substantial data and insight 
into DENV infection ranging from cytokine secretion and gene expression to epitope 
identification and receptor expression of infected peripheral blood mononuclear cells 
(PBMC) and specific cell types (i.e. DCs, macrophages, mast cells, and monocytes). 
Mosquito inoculation of primary skin explants has led to insight into targets of initial 
infection (Limon-Flores et al., 2005). Human umbilical vein endothelial cells (HUVEC) 
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and human dermal microvascular endothelial cells (HMVEC) have been used to 
characterize factors inducing endothelial cell permeability. However, primary cells have 
limited ability to be manipulated and are minimally permissive to transfection. 
 Cell culture models overcome the deficits in primary human cell models. 
Monocytic cell lines such as K562, THP-1, and U937 are highly permissive to infection, 
respond to ADE, and express a variety of clinically relevant soluble factors. The liver cell 
lines HepG2 and Huh7 have provided insight into the liver involvement during human 
DENV infection. Epithelial cell lines including the cervical cancer-derived HeLa cell 
line, adenovirus-transformed human embryonic kidney (HEK) 293 cell line, and SV40 
large T antigen-expressing HEK293T cell line support extensive manipulation and are 
highly transfectable. While these cell lines are more permissive to transfection and 
further manipulation, the relevance to human infection can be questionable. 
 Non-human cells have extensive uses in DENV research. The use of primary 
mouse cells such as fibroblasts and macrophages from manipulated mouse strains is one 
approach to overcome the inability to manipulate primary cells. However, these studies 
often require high viral titers. Non-human cells lines are predominantly used in viral 
propagation and titration, though they have been used for specific purposes in some 
studies. The Ae. albopictus larva cell line C6/36 is used for viral propagation as well as 
studies of DENV infection in mosquito cells. DENV propagation has also been 
performed in the African green monkey kidney epithelial Vero cell line while limited 
studies have been performed both in Vero and the similar COS cell lines. DENV titration 
has been done by intracellular antibody staining of Vero cells, similar to plaque titration 
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by staining of the rhesus macaque kidney cell line LLC-MK2 (Russell et al., 1967). 
DENV-induced apoptosis has been studied in baby hamster kidney (BHK) cell lines, 
consistent with their use in plaque assays as well. 
 Overall, while DENV research has been hampered by the lack of an accurate 
animal model, extensive tools have been developed providing many insights into 
infection. These studies have further highlighted and developed the roles of antibodies, T 
cells, liver cells, endothelial cells, epithelial cells, cytokines, and virus in the complex 
network of interactions that results in severe dengue. 
D. Disease-associated factors 
Viral and host factors have been implicated as potentially important to dengue 
pathogenesis. Host factors have been fairly well established, but viral factors remain 
more tenuous. As four evolutionary and antigenically distinct viruses, each DENV 
serotype has to some extent developed its own properties and must each be studied 
separately. Further, within each serotype, individual genotypes with different clinical 
properties have been identified. 
Host factor influence on DENV infection 
Human leukocyte antigen (HLA) genes are part of the major histocompatibility 
complex (MHC), proteins that present antigens to immune cells (Reviewed in Chaturvedi 
et al., 2006; Rothman, 2011). HLAs are differentiated into MHC class I and II. MHC 
class I proteins are expressed on the surface of nearly all somatic cells and mediate 
cellular immunity, presenting antigen to CD8
+
 T cells and NK cells. MHC class II 
proteins mediate immune activation, presenting on the surface of APCs to CD4
+
 T cells, 
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which in turn specify T helper type 1 (Th1) or T helper type 2 (Th2) responses. Specific 
HLAs bind have their own unique binding preferences, stimulating T cells that recognize 
those peptide/MHC complexes. Some HLA types have also been shown to associate with 
increased or decreased risk of severe dengue, with certain MHC class I (HLA-A*0203, 
HLA-A*29, HLA-A*33, HLA-B*13, HLA-B*14, HLA-B*44, HLA-B*52) and class II 
(HLA-DRB1*04) associated with DF and other MHC class I (HLA-A*0207, HLA-A1, 
HLA-A2, HLA-A*24, HLA-B*46, HLA-B*51) and class II (HLA-DQ1) alleles 
associated with DHF (Chaturvedi et al., 2006). Due to the close relationship of HLA type 
with T cell-mediated immunity, the association of specific HLA types with outcomes of 
DENV infection is an argument used in favor of the contribution of T cells to the 
outcome of DENV infection. 
Other gene associations are consistent with roles for antibodies and TNFα in 
severe dengue. Homozygotes for the Fcγ receptor II (FcγRIIA) gene variant with an 
arginine at position 131 have less capacity to opsonize IgG2 and may be protected from 
DHF (Loke et al., 2002). Conversely, heterozygous patients that have the TNFα-308A 
variant, which presumably leads to increased TNFα expression, have increased 
susceptibility to DHF (Loke et al., 2002; Perez et al., 2010) as well as asthma (Gao, 
2006) and diabetes mellitus (Settin et al., 2009), both diseases also associated with 
increased risk of DHF in Cuba (Kourp et al., 1987). Thus host factors associated with 
milder or more severe dengue are consistent with the current models of pathogenesis. 
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DENV influence on pathogenesis 
The strongest observation of the influence of the infecting DENV genotype is 
within DENV-2.  Prior to 1981, there were no documented cases of DHF in the Americas 
though DHF was widespread in Asia.  The first cases of DHF in the Americas were 
documented in Cuba during an epidemic in 1981 (Kourí et al., 1986).  Analysis of 
DENV-2 sequences from subsequent Jamaican outbreaks in 1981 and 1982, thought to 
represent the virus introduced to Cuba, revealed close homology to sequences from Thai 
and Vietnamese outbreaks (Rico-Hesse, 1990) suggesting that DHF in the Americas 
originated from introduction of an Asian DENV-2 genotype.  
Further evidence of the influence of infecting DENV on clinical outcome was 
presented from a prospective study in Iquitos, Peru (Watts et al., 1999). Following a 
DENV-1 epidemic in 1990, a cohort of students was serologically and clinically observed 
through a subsequent DENV-2 epidemic in 1995. The sero-conversion of this group was 
extrapolated to estimate the total expected cases of DHF and death among the same age 
group in the general populace. Despite the estimated 1,000 – 10,000 expected cases of 
DHF and DSS with 1-5% fatality rate in this age range, no cases were found and no 
deaths among children under 10 years old from 1994-1996 were attributed to hemorrhage 
or shock. Subsequent sequencing of DENV-2 samples from the epidemic identified the 
virus as an American genotype. Full genome analysis comparing Asian and American 
genotypes of DENV-2 revealed consistent single amino acid differences in prM, E, NS1, 
NS3, and NS4B proteins, multiple amino acid differences in NS5 and base changes in 
both 3’ and 5’ untranslated regions (UTRs; Leitmeyer et al., 1999). While these 
41 
 
observations remain only correlations with disease severity, it has been shown that there 
is decreased viral output in dendritic cells and monocytes infected with American 
genotype DENV-2 versus Asian genotype DENV-2 (Cologna and Rico-Hesse, 2003).  
A more recent report from Iquitos documented an outbreak of DENV-2 in 2010 
following outbreaks of DENV-3 and DENV-4 in 2008 and 2009, respectively (Durand 
Velazco et al., 2011). Higher rates of hospitalization and requests for hematocrit and 
platelet counts, laboratory tests used for management of dengue, as well as a 34.5% 
increase in the diagnosis of severe dengue symptoms were reported. 80% of reported 
cases of severe dengue were shock or vascular leakage. While part of these increases 
could have been due to the new guidelines for case management published by the WHO 
(WHO and TDR, 2009), the percentage of severe dengue cases with shock or vascular 
leakage indicate the new guidelines cannot account completely for these increases. 
Subsequent virus isolation, sequencing, and phylogenetic analysis confirmed grouping of 
this virus with other DENV-2 strains of Asian descent in the Americas, differing 
significantly from the virus responsible for the much milder 1995 outbreak (Mamani et 
al., 2011). Thus, while pathogenesis is immune mediated, the infecting virus itself plays a 
significant role in determining disease severity. 
E. DENV, inflammation, and IL-8 
The cytokine storm and resulting extreme inflammation that occurs during severe 
dengue has led to a number of studies correlating inflammatory mediators with the 
severity of infection. Some of those mediators are listed in Table I-2. The study of 
inflammatory mediators has ranged from clinical studies down to cell culture models, 
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incorporating ADE, complement, T cell cross-reactivity, and direct viral infection all as 
potential mechanisms leading to cytokine storm. However, each mediator has its own 
properties and regulation, varying by cell type, leading to a complex network of 
interactions.  
Early DENV infection 
Inflammation begins in human DENV infection with the inoculating mosquito 
bite.  Factors within the mosquito saliva, DENV binding and infection of Langerhans 
cells, and more recently characterized DENV infection of basal keratinocytes lead to 
increased mRNA and expression of innate pattern recognition receptors (PRRs) 
(Surasombatpattana et al., 2011). Many of these PRRs upregulated during infection are 
activated by double-stranded RNA (dsRNA), and include RIG-I, MDA-5, protein kinase 
R (PKR) (Surasombatpattana et al., 2011), and TLR3 (Tsai et al., 2009; Nasirudeen et al., 
2011). In addition, the TLR adapter protein myeloid differentiation factor 88 (MyD88) is 
also upregulated (Surasombatpattana et al., 2011). Transcription factors interferon 
response factors 7 (IRF7) and NF-κB are both activated early after infection leading to 
upregulation of IFN-β and TNFα (Hoang et al., 2010; Bustos-Arriaga et al., 2011). 
DENV infection-induced maturation of DCs (Ho et al., 2001; Libraty et al., 2001) 
promotes migration back to lymph nodes where further viral dissemination to immune 
cells is presumed to occur. 
IFN is an early regulator of infection that plays a substantial role in determining 
the outcome of infection. This is exemplified in the IFN receptor deficient AG129 mouse 
model (Tan et al., 2010) and further exemplified by the number of DENV proteins that 
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have been shown to interfere with the IFN response (Muñoz-Jordan et al., 2003; Ashour 
et al., 2009), both of which were described above. IFN-β activates localized intracellular 
defenses and is an effective antiviral against DENV infection (Diamond et al., 2000; 
Diamond and Harris, 2001). Activation of interferon-stimulated response elements 
(ISREs) leads to further expression of PKR, 2’,5’-oligoadenylate synthase (2’,5’-OAS), 
dsRNA-activated myxovirus defense genes (MxA and MxB), and inducible nitric oxide 
synthase (iNOS; Samuel, 2001). IFNs have been noted to substantially prevent infection 
in culture (Diamond et al., 2000; Diamond and Harris, 2001), but have little effect 
clearing cells already infected with DENV (Diamond and Harris, 2001).  
Similarly, IFN is noted to work with another important mediator, TNFα, to 
regulate the timing of endothelial cell permeability (Liu et al., 2009). The substantial 
effect of TNFα on vascular permeability was demonstrated by adding TNFα-blocking 
antibody to infected monocyte culture supernatants (Anderson et al., 1997). Intercellular 
adhesion molecule-1 (ICAM-1) is upregulated on activated endothelium, binds to 
integrins on leukocytes, and is a marker of endothelial cell permeability. Pre-treatment of 
supernatants with anti-TNFα antibody inhibited ICAM-1 expression in HUVEC. IFN was 
noted to suppress TNFα-induced hyperpermeability of endothelial cells at day 3 post-
infection, but enhance TNFα-mediated hyperpermeability after one week of infection 
(Liu et al., 2009). Thus, early effects of these inflammatory mediators are protective, yet 
over time, may help enhance pathogenesis. 
TNFα generally promotes an inflammatory state and upregulates a variety of other 
genes through the TNFα receptors (TNFRs) and subsequent NF-κB activation (Reviewed 
44 
 
in Parameswaran and Patial, 2010). TNFα production is activated by PRRs, NF-κB 
signaling, and positively regulates itself. IL-6, IL-8 and number of other cytokines have 
been shown to be upregulated by TNFα in both infected and uninfected cells. As dengue 
pathogenesis continues, these and other cytokines are upregulated both directly by 
infection and through activation by TNFα and through other secondary mediators. 
Other inflammatory mediators 
IL-6, IFNγ, CXCL-9, CXCL-10 and IL-10 are all associated with severe dengue. 
IL-6 generally promotes fever associated with DENV infection. Early expression of IFNγ 
is associated with less severe dengue (Rothman, 2011). Conversely, increased IFNγ 
and/or TNFα production from T cells paired with decreased expression of CD107a, a 
degranulation marker, is associated with DHF (Duangchinda et al., 2010), correlating 
with the association of increased, late IFNγ with severe dengue (Rothman, 2011). CXCL-
9, -10, and -11 are IFNγ-inducible chemokines that use CXCR-3 and have been 
demonstrated to be associated with severe human infection (Dejnirattisai et al., 2008). 
Yet CXCR-3 was found to be protective during mouse infection with DENV (Hsieh et 
al., 2006) with this protection mediated by CXCL-10 (Chen et al., 2006; Hsieh et al., 
2006; Ip and Liao, 2010), highlighting the differences in mouse models of DENV 
infection versus human dengue. IL-10 is associated with CD4
+
 Th2-type responses and is 
an inhibitory factor of TNFα. Greater amounts of IL-10 were shown to be produced both 
in children with DHF (Green et al., 1999) and late in DENV-infected PBMC culture 
(Chaturvedi et al., 1999). While each of these factors is associated with DHF and severe 
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infection, the exact contributions to severe dengue and specifically vascular leakage are 
not clear. 
Another important inflammatory mediator and antiviral is NO. As previously 
mentioned in association with NS5, DENV strains associated with resistance to the 
antiviral effect of NO also correlate with increased NO secretion (Ubol, 
Chareonsirisuthigul, et al., 2008).  Upregulation of iNOS produces NO, and this process 
was implicated in endothelial cell damage in mouse and human cell culture in concert 
with TNFα (Yen et al., 2008). However, increased NO is associated with DF while 
decreased NO is associated with DHF (Valero et al., 2002). One potential explanation for 
this is that viral entry mediated through ADE suppresses iNOS transcription 
(Chareonsirisuthigul et al., 2007). Therefore, the role of NO may be generally protective 
during dengue, but the exact role and mechanism remains unclear. 
A DHF-associated inflammatory mediator with a much clearer association with 
vascular leakage is IL-8 (Raghupathy et al., 1998; Juffrie et al., 2000; Bosch et al., 2002; 
Medin et al., 2005). IL-8 is a chemokine classically associated with neutrophil 
recruitment and vascular endothelium permeability, but it also interferes with the antiviral 
actions of IFN-β (Polyak et al., 2001). One current cell culture model of infection 
implicates IL-8 and TNFα as the primary mediators of endothelial permeability (Kelley et 
al., 2012). Further, while IL-8 has been shown to be secreted from many different cells at 
high levels after DENV infection, little is known about the exact mechanism of DENV-
induced IL-8 production. 
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Yet the importance of IL-8 to DENV infection in particular remains unknown. 
DENV proteins NS5 (Medin et al., 2005; Pryor et al., 2007; Rawlinson et al., 2009), C 
(Li et al., 2010), and NS4B (Kelley et al., 2011, 2012) have been shown to induce IL-8 
secretion. The association of decreased nuclear import of NS5 with increased IL-8 
production and decreased virus replication (Pryor et al., 2007), as detailed above (see 
Non-Structural Protein 5), led the authors to propose a regulatory model of IL-8 
production. This model was based on a study in HCV (Koo et al., 2006). During this 
study, a model of acute HCV infection was compared to a model of chronic HCV 
infection. The model of acute infection measured replication efficiency following 
transfection of Huh7 cells with different HCV replicons. Huh7 cells that were weakly 
permissive to HCV replicon transfection showed decreased replication. Huh7 cells that 
had been cured of HCV replicon infection were strongly permissive to subsequent HCV 
replicon transfection and showed increased replication. In addition, strongly permissive 
Huh7 cells showed decreased ability to induce IL-8 as compared to weakly permissive 
Huh7 cells. The model of chronic infection was Huh7 or BB7 cells with stably 
transfected HCV replicons. The authors used both small interfering RNA (siRNA) to 
knockdown IL-8 mRNA and, separately, antibody to IL-8 to neutralize IL-8 protein. With 
both methods of IL-8 inhibition, the authors saw reduced HCV replicon replication. This 
correlated with increased HCV NS5A protein expression observed when BB7 cells stably 
transfected with HCV replicon were stimulated with exogenous IL-8. Thus, the authors 
concluded that IL-8 was inhibitory to acute HCV infection but positively correlated with 
chronic HCV infection. Whether IL-8 has antiviral properties and what they may be has 
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yet to be determined. Further, the effects of IL-8 on DENV infection and replication 
remain to be determined. 
Several downstream effects of IL-8 correlate with severe dengue. Though 
classically associated with neutrophil recruitment, IL-8 acts as a chemokine on a variety 
of cells that express either or both the CXCR-1 and CXCR-2 receptors, including 
monocyte-derived DCs, macrophages, mast cells, and subsets of both T cells and NK 
cells. As DCs, macrophages and mast cells are thought to be primary targets of infection, 
recruitment of these cells to sites of infection by IL-8 is a potential model for recruitment 
of new target cells for DENV infection. One of the IL-8 receptors, CXCR1, is selectively 
expressed on effector memory CD8
+
 T cells (Takata et al., 2004), presenting a possible 
model of selective recruitment during secondary DENV infection. In addition, IL-8 acts 
directly on endothelial cells, inducing the formation of gap junctions in the vascular 
endothelium to allow passage of immune cells to the site of infection . IL-8-induced 
vascular endothelial cell permeability does not damage the endothelium (Elliott and Finn, 
1993; Mukaida, 2000). Thus, IL-8 by itself provides a potential mechanism of vascular 
endothelial cell permeability without cell damage, the hallmark of severe dengue. 
Transcriptional regulation of IL-8 
The IL-8 promoter is predominantly regulated by three transcription factors in the 
first -133 bp upstream of the transcription start site: AP-1, C/EBP, and NF-κB (Mukaida, 
2000).  The exact number and role of more distal promoter elements is not clear, but 
IFNγ activated STAT3 has been demonstrated to bind -537 bp upstream of the 
transcription start site (Gharavi et al., 2007). Our original study demonstrated differential 
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activation of the transcription factors that control the IL-8 promoter between HEK293 
and HepG2 cells (Medin et al., 2005). Perhaps more intriguingly, inhibition of IL-8 by 
clinically relevant anti-inflammatory pharmaceuticals demonstrated mixed results (Medin 
and Rothman, 2006). SB203580 is a p38 mitogen-activated protein kinase (MAPK) 
inhibitor. Rolipram is a phosphodiesterase IV inhibitor. Dexamethasone is a 
glucocorticoid. In HEK293A cells, SB203580, rolipram, and dexamethasone reduced 
induction by less than half of untreated cells. C/EBP-mediated promoter activation was 
unchanged while NF-κB-mediated promoter activation was only inhibited by 
dexamethasone. AP-1-mediated transcription was increased by both SB203580 and 
dexamethasone. In HepG2 cells, DENV-mediated IL-8 promoter activation was inhibited 
by rolipram, but dexamethasone had no effect and SB203850 enhanced IL-8 promoter 
activation. As in HEK293A cells, there was no change in C/EBP-mediated promoter 
activation by these pharmaceuticals in HepG2 cells. There was also no change in NF-κB-
mediated promoter activation. However, AP-1-mediated promoter activation was 
increased by SB203580, consistent with IL-8 promoter activation, and increased by 
rolipram, opposite the IL-8 promoter activation. Together, these results suggest that 
DENV has multiple mechanisms to induce IL-8 activation in infected cells. One 
possibility is that one protein, NS5 (Medin et al., 2005), mediates activation of multiple 
signaling pathways, depending on cell type. Another possibility is that DENV has 
multiple mechanisms to induce signaling pathways that lead to AP-1, C/EBP and/or NF-
κB activation and activation of IL-8 transcription. Further, Medin et al. (2006) 
demonstrated variable, even opposing effects of these pharmaceuticals on the secretion of 
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IL-8 as compared to IL-8 promoter activation that depended, not only on the 
pharmaceutical, but also on the cell type. This suggests a possible disconnect between IL-
8 promoter activation and post-transcriptional regulation of IL-8 (detailed below). 
Of the transcription factors that regulate the IL-8 promoter, NF-κB has been noted 
several times to be upregulated and activated during DENV infection in several different 
cell types. This correlates with NF-κB as an early, central regulator of the inflammatory 
response, activated by many PRRs. In hepatic cells, NS1 has been shown to activate NF-
κB (Silva et al., 2011). NF-κB is a homo- or heterodimer of p65 and p50. NF-κB 
associates with the inhibitory κB subunit (IκB) within the cytoplasm, until 
phosphorylation of IκB in the IκB kinase (IKK) complex causes dissociation, allowing 
NF-κB to re-localize to the nucleus and initiate transcription of target genes (Liu et al., 
2012). NF-κB target genes include TNFα, IL-6, IL-8, and RANTES. The NF-κB binding 
site of the IL-8 promoter is adjacent to the binding site of NF-κB repressing factor (NRF). 
In the presence of NF-κB, NRF becomes a co-activator (Mukaida, 2000).  
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Figure I-4: Transcriptional and post-transcriptional regulation of IL-8. 
IL-8 is activated by a number of stimuli. TNFR is shown here as example. Signaling is 
predominantly occurs through activation of MAPK pathways JNK and p38 as well as 
activation of NF-κB. Subsequent activation of the transcription factors AP-1, C/EBP, 
and/or NF-κB in the cytoplasm leads to their translocation into the nucleus, then binding 
and activation of the IL-8 promoter. IL-8 mRNA is further regulated post-
transcriptionally, predominantly through association of the ARE of the IL-8 3’ UTR with 
KSRP, though other ARE BPs have been demonstrated to also bind. Constitutive 
association of KSRP with the IL-8 mRNA targets IL-8 mRNA for degradation. 
Stimulation of p38 leads to dissociation and degradation of KSRP, increasing IL-8 
mRNA half-life. In all cell types besides endothelial cells, mRNA stabilization leads to 
translation and secretion of IL-8. In endothelial cells, secretion of IL-8 is further 
regulated by IL-8 association with vWF, sequestering IL-8 until endothelial cells are 
stimulated to release vWF. Based on Hoffmann et al., 2002. 
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 AP-1 is less well studied in DENV infection. The predominant MAPK pathway 
that is thought to initiate AP-1 activation is terminally mediated by the Jun amino-
terminal kinase (JNK), which phosphorylates one or more Jun family proteins within the 
cytoplasm (Reviewed in Mechta-Grigoriou et al., 2001). Phosphorylation leads to homo- 
or hetero-dimerization of Jun proteins with Fos or ATF families of proteins and re-
localization of AP-1 dimers to the nucleus, mediating transcription of target genes. 
Studies of the AP-1 pathway in DENV predominantly focus on JNK activation which 
occurs early in infection, as in (Ceballos-Olvera et al., 2010). 
 A closer examination of subcomponents of AP-1 has been lacking in the context 
of DENV. While Jun family proteins are well associated with protein activation, Fos 
family proteins, in particular c-Fos, Fra-1, and Fra-2, have been noted in certain contexts 
to be either activating or inhibitory (Adiseshaiah et al., 2006). Heterodimers of Fos 
proteins provide a potential regulatory model of IL-8 activation, correlating with the 
proposal of the authors of (Pryor et al., 2007). 
 Less is known about C/EBP, also known as nuclear factor-IL-6 (NF-IL-6), though 
two isoforms are known to exist. C/EBPα is expressed exclusively in liver cells while the 
C/EBPβ form is expressed more ubiquitously. Within DENV-infected liver cells, C/EBP 
in parallel with an unknown factor, was shown to regulate RANTES expression (Lin et 
al., 2000). However, outside our more recent study demonstrating C/EBP activation in 
HEK293A cells (Medin et al., 2005), little else is known about the role of C/EBP during 
DENV infection. 
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Post-transcriptional regulation of IL-8 
Post-transcriptional regulation of the mRNA of inflammatory mediators is a 
relatively new field of study.  Adenine and uridine rich elements (ARE) in the 3’ UTR of 
mRNAs are bound by specific binding proteins (ARE-BPs).  The binding of an ARE-BP 
changes the stability of the mRNA target mediating stabilization, targeting for ARE 
mediated decay (AMD), or sequestering the bound mRNA in processing (P) bodies 
(Reviewed in Eulalio et al., 2007). The IL-8 3’ UTR contains one ARE. In the case of 
TNFα mRNA, there are multiple AREs that can bind several ARE-BPs, which 
cooperatively determine TNFα mRNA stability. 
The best characterized mediator of IL-8 mRNA stability is the ARE-BP KH-type 
splicing regulatory protein (KSRP; Abdelmohsen et al., 2008). KSRP is constitutively 
expressed, binds and destabilizes target transcripts by initiation of AMD, acting as a 
negative regulator of target mRNAs. Besides IL-8, known mRNA targets for KSRP 
include TNFα, iNOS, at least two forms of type I interferon (Lin et al., 2011), IL-2, c-
Fos, and c-Jun. Regulation of KSRP is through phosphorylation by p38 causing 
dissociation of KSRP from the target ARE and stabilization of mRNA transcripts (Lin et 
al., 2011). 
However, the post-transcriptional regulation of IL-8 may be more complex. Two 
other ARE-BPs have been shown to regulate IL-8 mRNAs in specific systems. 
Tristetraprolin (TTP) is a zinc finger protein. Like KSRP, TTP is an ARE-BP that 
initiates AMD (Eulalio et al., 2007). TTP has been shown to be capable of binding and 
downregulating IL-8 mRNA in a model of cystic fibrosis (Balakathiresan et al., 2009). 
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Also destabilizing, the ARE-BP Human antigen R (HuR) has been implicated to bind IL-
8 mRNA in CNS tumors (Nabors et al., 2001). Finally, one study suggested that IL-8 
itself may mediate downregulation of ARE-BPs (Bautista et al., 2009) though both the 
mechanism and the target ARE-BPs were not identified. As such, the post-transcriptional 
regulation of IL-8 may be more complex than simple association and dissociation of 
KSRP. 
Further post-translational regulation of IL-8 occurs within endothelial cells.  IL-8 
protein binds von Willebrand factor (Bierings et al., 2007) targeting and sequestering IL-
8 in Weibel-Palade bodies (WPBs; Rondaij et al., 2006).  Stimulation with thrombin or 
epinephrine, which increase intracellular Ca
2+
 or cyclic AMP, induces fusion of WPBs 
with the plasma membrane and release of WPB contents, including IL-8, into the 
extracellular space (Rondaij et al., 2006). 
Recent studies of DENV-induced IL-8 
Two groups have recently published studies on IL-8 activation by other DENV 
proteins. The first implicated C in activation of IL-8 through P-TEFb (Li et al., 2010). 
This study implicated C as directly binding the IL-8 promoter, mediating enhancement 
through the NF-κB binding site. NS4B has also been characterized as inducing IL-8 
secretion and possibly contributes to dengue pathogenesis (Kelley et al., 2011, 2012). 
First, transfection with a plasmid expressing NS4B was shown to mediate IL-8 secretion 
in the monocytic THP-1 cell line. They further demonstrated that polyprotein processing, 
as determined by 2K cleavage from NS4B, enhanced IL-8 secretion (Kelley et al., 2011). 
However, this study did not address a possible contribution either of NS4B or other 
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DENV proteins to activation of the IL-8 promoter. The subsequent study from this group 
implicated NS4B-mediated IL-8 and TNFα secretion from THP-1 cells as determinants of 
endothelial cell permeability (Kelley et al., 2012), thus further emphasizing the possible 
importance of IL-8 and determinants of IL-8 secretion to pathogenesis.  
F. Objectives of thesis 
IL-8 induction has been an almost ubiquitous correlate of dengue pathogenesis 
and feature of DENV infection in vitro. While studies had characterized the requirements 
for IL-8 induction by NS5, comparatively little attention had been given to the possible 
contribution of other DENV proteins.   
At the beginning of this study, we had preliminary data that plasmids expressing 
DENV prM-E (the polyprotein segment encompassing both prM and E) or C activated 
IL-8 transcription (Medin, 2005 and unpublished results) though plasmids expressing C, 
prM, or E alone did not induce IL-8 secretion (Medin et al., 2005). These preliminary 
data were supported by evidence that multiple DENV proteins interacted with IFN 
signaling pathways (Muñoz-Jordan et al., 2003; later Ashour et al., 2009), shown to be 
particularly important to infection. Studies that have followed up on IL-8 induction by 
NS5 specifically have only looked at IL-8 secretion and not transcriptional activation 
(Pryor et al., 2007; Rawlinson et al., 2009).  
Further correlations such as 1. mutations within NS5 increased IL-8 along with 
NO induction (Ubol, Masrinoul, et al., 2008) and 2. NS4B induction of both IL-8 and 
TNFα (personal communications later published in Kelley et al., 2011, 2012) suggested 
there might be common signaling pathways and activation of transcription factors 
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mediating inflammatory cytokine promoter activation. As we were already prepared from 
our previous study (Medin et al., 2005), closer examination of the transcription factors 
mediating IL-8 promoter activation was a natural extension of our first screen. 
We hypothesized that: 
a. Multiple DENV proteins contribute to the transcriptional activation 
of IL-8 during DENV infection.   
b. Expression of DENV NS5 activates other cytokines regulated by the 
transcription factors AP-1, C/EBP and NF- κB.  
c. DENV proteins that activate the IL-8 promoter do so by activating 
one or more of the individual transcription factors AP-1, C/EBP and 
NF-κB. 
This work is presented in two parts: 
Aim 1: Examine the activation of the IL-8 promoter by DENV infection and expression 
of DENV proteins. These studies addressed the following questions: 
 What is the profile of IL-8 promoter activation and IL-8 mRNA production by 
DENV? 
 Does expression of DENV proteins other than NS5 activate IL-8 transcription? 
 Does NS5 induce IL-8 promoter activation in other cell types? 
 Does expression of NS5 activate transcription of other cytokines? 
 What regions of NS5 are important to NS5-driven IL-8 promoter activation? 
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Aim 2: Characterize the activation of transcription factors within the IL-8 promoter by 
DENV proteins. These studies addressed the following questions: 
 Does activation of the IL-8 promoter by DENV proteins depend on any single 
transcription factor? 
 What individual transcription factors are activated by DENV proteins? 
 Does differential activation of activating and inhibitory subunits of AP-1 
contribute to the regulation of IL-8 promoter activation? 
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CHAPTER II: MATERIALS AND METHODS 
 
A. Cells and cell culture 
HEK293A cells were purchased from Invitrogen Life Technologies and HeLa 
cells were purchased from American Type Culture Collection (ATCC). Both were 
maintained in High Glucose Dulbecco’s Modified Eagle’s Medium (Invitrogen Life 
Technologies) supplemented with 10% fetal bovine serum (Hyclone), 100 U/mL 
Penicillin, 100 μg/mL Streptomycin, and 0.1 mM non-essential amino acids (Gibco).   
Vero cells and C6/36 cells were obtained from ATCC and maintained in 
Minimum Essential Media (Invitrogen Life Technologies) supplemented with 10% fetal 
bovine serum (Hyclone) and 100 U/mL Penicillin, 100 μg/mL Streptomycin (Gibco).  
C6/36 cells were maintained at 29° C while all other cell lines were maintained at 37° C. 
B. Virus and infection 
Dengue virus (DENV) type 2 strain New Guinea C (NGC) was propagated in 
C6/36 cells and titrated by limiting dilution plaque assay on Vero cells. Cells were 
infected as previously described (Medin et al., 2005).  Briefly, virus at the indicated MOI 
was added to cells, then incubated at 37° C for 1 or 2 hours, shaking gently every 20 
minutes.  Following incubation, cells were washed twice with PBS then incubated for the 
indicated time with complete medium. 
To concentrate virus, infected C6/36 cell supernatants were submitted to 
ultracentrifugation and pellets were resuspended in of HEK293A complete media. 
Concentrated virus was titrated by limiting dilution plaque assay on Vero cells. 
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C. Cloning and plasmids 
All DENV protein expression constructs were constructed using the Gateway 
System (Invitrogen Life Technologies) per the manufacturer’s recommendations. DENV 
proteins were previously cloned (Medin et al., 2005; Table III-1) with published primers 
based on the DENV NGC infectious clone (Polo et al., 1997).  Briefly, amplicons 
generated by PCR were inserted into the pDONR221 expression vector (Figure III-2) by 
recombination utilizing the attB recombination sequences included on the primers (Table 
III-1). Following sequencing (Figure III-2A-F; Table III-2), inserts were transferred 
through a second recombination reaction into the pDEST40 expression vector driven by 
the constitutive CMV promoter (Figure III-2G).  There is an error within the genome 
annotation (GenBank ID: M29095). As a result, the NS4A amplicon contains the coding 
sequence for the amino terminal 136 amino acids of NS4B protein and the NS4B 
amplicon contains only the remaining 112 amino acid carboxy-terminus. Truncated NS5 
(NS5-N320, NS5-N368, and NS5-C270) were generated using previously published NS5 
primers (Table III-1; Medin et al., 2005) and respective primers for the 3’ or 5’ ends of 
each truncation (Table III-4). The NS5 polymerase active site, GAA, was mutated to 
GDD using the site directed mutagenesis kit (Stratagene) per manufacturer instructions 
and a mutagenesis primer (Table III-5). 
NS1, NS1G, NS3 and NS5 inserts in pDONR221 were additionally transferred 
into the pDEST47 enhanced green fluorescent protein (eGFP) tagged expression vector 
(Figure III-6). Transfer was performed by Gateway LR recombination reaction per 
manufacturer recommendations (Invitrogen). Control plasmids used were the included 
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Gateway eGFP control plasmid, pcDNA/GW-47/CAT (pCAT-eGFP; Figure III-5) and 
pmaxGFP (Lonza; Figure III-5). 
Luciferase reporter plasmids used during these studies were previously described 
(Medin et al., 2005).  Briefly, the IL-8 promoter (Figure II-1A) and IL-8 promoter 
constructs mutated at the AP- 1 (TGACTCA to TATCTCA from - 126 to - 120), C/EBP 
(CAGTTGCAAATCGT to AGCTTGCAAATCGT from -94 to -81), or NF-κB 
(GGAATTTCCT to TAACTTTCCT from -80 to -71) binding sites (Okamoto et al., 
1994; Figure II-1C) were generously provided by Naofumi Mukaida (Kanazawa 
University, Japan). AP-1-, C/EBP-, and NF-κB-driven luciferase plasmids (Figure II-1B) 
were obtained from Stratagene. Each promoter region contains tandem repeats of 
consensus binding sites: the AP-1 promoter contains seven tandem repeats, the C/EBP 
reporter contains three tandem repeats, and the NF-κB reporter contains five tandem 
repeats. Sequence comparisons of all AP-1, C/EBP, and NF-κB binding sites are shown 
in Table II-1. A RANTES promoter-driven luciferase construct and a plasmid expressing 
MAL, used as a positive control, was generously provided by Kate Fitzgerald (University 
of Massachusetts Medical School). 
 All plasmids were propagated in Top10 E. coli (Invitrogen) and purified using the 
endotoxin free maxiprep kit (QIAgen).  
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Figure II-1: Diagrams of inducible luciferase reporter plasmids. 
(A) Diagram of the IL-8 promoter-driven luciferase reporter and transcription factor 
binding sites. The -133 IL-8 promoter contains binding sites for AP-1, C/EBP, and NF-
κB (black, bold). Nucleotides critical to transcription factor binding are underlined. 
Repressors are also shown (red, bold). The repressor OCT-1 binding site overlaps the 
C/EBP binding site. The repressor NRF partially overlaps the NF-κB binding site and 
becomes a co-activator when NF-κB binds. (B) Diagrams of AP-1, C/EBP, and NF-κB 
reporter plasmids (Stratagene). Tandem consensus binding sites for each transcription 
factor drive the expression of firefly luciferase. The AP-1 reporter plasmid contains seven 
tandem binding sites for AP-1. The C/EBP reporter contains three tandem consensus 
binding sites for C/EBP. The NF-κB reporter contains five tandem consensus binding 
sites for NF-κB. (C) Representation of IL-8 mutant reporter plasmids previously 
published (Okamoto et al., 1994). The IL-8 reporter mutated at the AP-1 site does not 
bind AP-1, but can bind C/EBP and NF-κB. The IL-8 reporter mutated at the C/EBP 
binding site does not bind C/EBP, but can bind AP-1 and NF-κB. The IL-8 promoter 
mutated at the NF-κB binding site does not bind NF-κB, but can bind AP-1 and C/EBP. 
A comparison of binding sequences is shown in Table II-1.  
A 
B 
C 
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Table II-1: Comparison of AP-1, C/EBP, and NF-B binding motifs, consensus binding sites, IL-8 promoter 
binding sites and IL-8 mutant binding sites. 
 AP-1 C/EBP NF-κB 
Binding Motif TGA(G/C)TCA T(T/G)NNG(C/T)AA(T/G) GGGRNNYYCC 
Consensus Binding 
Sequence
1
 
TGAGTCA TTGTGCAAT GGGACTTTCC 
IL-8 Promoter Binding 
Sequence
2
 
-126TGACTCA-120 -93AGTTGCAAAT-84 -82TGGAATTTCC-72 
Mukaida IL-8 mutant
3
 
-126TATCTCA-120 -94AGCTTAGCAAAT-84 -82TTAACTTTC-72 
 
1. From Stratagene. 
2. Le et al., 2000. 
3. Okamoto et al., 1994.  
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D. Transfections 
Samples for qRT-PCR analysis were transfected in 6-well plates using 
Lipofectamine 2000 (Invitrogen Life Technologies) per manufacturer instructions.  
Briefly, 4 x 10
5
 cells were plated and transfected with the indicated plasmid at a reagent 
to plasmid ratio of 1:4.  Cells were incubated for 24, 48 or 72 hours before harvest. 
Samples for luciferase assays were transfected in 96-well plates as previously 
described (Medin et al., 2005).  Briefly, 2 x 10
4
 cells were transfected with a total of 180 
ng of DNA using the Genejuice transfection reagent (Novagen) per manufacturer 
recommendations.  To equilibrate all volumes and total amounts of transfected DNA, 
pcDNA 3.1 was added where needed.  Cells were incubated 24 hours prior to luciferase 
assay (below) or infection with DENV as described above. 
E. Dual Luciferase Reporter Assay 
Dual luciferase assays were performed as previously described (Medin et al., 
2005).  Briefly, supernatants were removed and cells were lysed with passive lysis buffer 
(Promega).  Aliquots of lysate were distributed in duplicate 96-well plates (Costar) prior 
to the addition of either firefly luciferase substrate (Promega) or appropriately diluted 
native coelenterazine (Biotium).  Luminescence was measured immediately after 
substrate addition on a Perkin Elmer Envision multilabel plate reader.  Data analysis was 
performed using Microsoft Excel and Prism Graphpad software. 
F. TaqMan quantitative RT-PCR 
Quantitative real time RT-PCR was performed using the TaqMan system and 
reagents.  RNA was isolated using the RNeasy mini kit (QIAgen). Total RNA was 
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quantitated by absorbance at 260 nm, and then diluted to 100 ng/μL.  RNA samples were 
reverse transcribed using a two-step TaqMan cDNA synthesis kit (Applied Biosystems).  
Amplification was performed using TaqMan PCR mix and 20x primer/probe mixes for 
IL-8, TNFα, β-actin, and GAPDH mRNA (Applied Biosystems) per manufacturer 
recommendations.  Analysis was performed on the ABI 7300 Real-Time PCR System.  
Further data analysis was performed using Microsoft Excel and Prism Graphpad 
software. 
G. Flow cytometry 
Flow cytometry sample preparation was performed as previously described and 
cell sorting was performed by the University of Massachusetts flow cytometry core 
facility. All adherent cells were trypsinized prior to analysis. Briefly, cells transfected 
with enhanced green fluorescent protein (eGFP) tags were either submitted to live 
analysis or fixed with ABI fixative solution (see below). Live cell gating in fixed cells 
was validated by comparison between live and fixed eGFP expressing cells. DENV-2 
infected cells were fixed and permeabilized with ABI fixative and permeabilization 
solution. Mouse DENV-2 E-specific antibody 3h5 was used to quantify infection and 
anti-mouse fluorescein isothiocyanate (FITC) conjugated antibody was used for detection 
of 3h5. Gating and analysis was with FloJo software with graphs generated using Prism 
Graphpad. Results are presented as percent of live cells.  
H. Fluorescent Microscopy 
Fluorescent microscopy was performed on live cells cultured in 6-well plates 48 
hours post-transfection using an Evos fl fluorescent microscope. Image adjustment, 
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capture, and overlay was performed using the integrated microscope system software. 
Image adjustments were made prior image capture and applied to all images equally. 
I. PCR Array 
RNA samples prepared as above were further purified and analyzed by qPCR 
array (SA Biosciences). 100 ng of each RNA sample was treated with DNase I to ensure 
elimination of genomic DNA, and then cDNA was synthesized using the RT
2
 First Strand 
Synthesis kit (SA Biosciences) per manufacturer recommendations. RT
2
 ABI-specific 
SYBR Green/ROX qPCR Master Mix (SA Biosciences) was then added to the cDNA, the 
mixture was added to the human common cytokine array (SA Biosciences), and the array 
was analyzed on an ABI 7300 Real-Time PCR system per manufacturer instructions 
(Applied Biosystems). Data analysis was performed using the Microsoft Excel template 
provided by the manufacturer. 
J. Enzyme-Linked Immunosorbant Assay (ELISA) 
Sandwich ELISA was performed using the IL-8 or TNF DuoSet ELISA 
development system (R&D Systems) per manufacturer instructions. Briefly, provided IL-
8- or TNF-specific capture antibody was bound to 96-well plates at 37° Celsius for 2 
hours (overnight at 4° Celsius was also attempted). Following blocking of wells with Ig 
depleted bovine serum albumin (Hyclone), standards and supernatants were added to 
each plate and incubated overnight at 4° C. Sample wells were washed, incubated with 
horse radish peroxidase (HRP)-conjugated detection antibody, then developed with 3,3’-
5,5’ tetramethylbenzidine (TMB; Dako) colorometric HRP substrate. TMB reaction was 
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stopped with 1 Normal hydrochloric acid and the results were quantitated by 
measurement of the colorometric product at 405 nm on a plate reader. 
K. Transcription factor analysis  
The AP-1 binding site in the IL-8 promoter sequence was compared by computer 
analysis to the corresponding mutated AP-1 binding site (Figure III-15). This analysis 
used the internet-based software PROMO  
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3), 
TFSEARCH (http://mbs.cbrc.jp/research/db/TFSEARCH.html), TFBIND 
(http://tfbind.hgc.jp/), and JASPAR (http://jaspar.binf.ku.dk/). The last repeat analysis 
was performed on April 17, 2012. 
To analyze components of AP-1 that could bind the IL-8 promoter, we used the 
FactorFinder kit (Miltenyi). Following infection, cells were lysed at 0, 6, 24, 48, and 72 
hours post infection and analyzed for transcription factor activation per manufacturer’s 
recommendations. Forward and reverse sequences conjugated to streptavidin and used for 
transcription factor capture were derived from the IL-8 -133 bp consensus promoter 
(AGATCTGAAGTGTGATGACTCAGGTTTGCCCTGAGGGGATGGGCCATCAGTT
GCAAATCGTGGAATTTCCTCTGACATAATGAAAAGATG) and obtained from 
Eurofins MWG Operon. IL-8 promoter sequence was conjugated to µMACS beads, 
incubated with cell lysates, and beads were washed to ensure removal of unbound 
protein. IL-8 promoter-bound proteins were eluted using Laemelli sample buffer (Bio-
Rad) and analyzed by SDS-PAGE and western blot. Antibodies used for detection were 
anti-c-Jun (Active Motif), anti-Fra-1 (Santa Cruz), and anti-Fra-2 (Active Motif). 
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Activation of c-Jun has been previously demonstrated during DENV infection (Ceballos-
Olvera et al., 2010) and was used as a positive control. Additional detection was 
performed on µMACS flow through to verify the presence of c-Jun in lysates. 
L. Statistical Analysis 
Statistical analysis was performed using Prism Graphpad. For Figure III-3 and 
Figure III-13 we compared each DENV expression plasmid and dosage using 2-way 
ANOVA. To compare each of the dosages for individual expression plasmids, we used 
the Bonferroni post-test. For Figure III-13B and Figure III-13C, we further compared 
each column of values to 1, the arbitrary pcDNA value (null hypothesis of no effect) by 
single sample t-test.  For Figure III-9, we compared the 40 ng dosage of NS5 with the 
100 ng dosage of NS5 by paired, 1-tailed t test. For Figure III-12, we compared each 
sample to pcDNA, the negative control, using paired, 2-tailed t test. For Figure III-14, we 
compared expression plasmids and luciferase reporter, also using 2-way ANOVA. To 
compare each luciferase reporter for individual expression plasmids, we used the 
Bonferroni post-test. For Figure III-14, we further analyzed our data set using the non-
parametric Wilcoxon matched pairs signed rank test.  
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CHAPTER III: RESULTS 
 
Aim 1 
The first aim of this work focused on examining the activation of the IL-8 promoter 
by DENV infection and expression of DENV proteins. This part of the study addressed 
the following questions: 
 Does expression of DENV proteins other than NS5 activate IL-8 transcription? 
 Does expression of NS5 activate transcription of other cytokines? 
 What regions of NS5 are important to NS5 driven IL-8 promoter activation? 
 
A. Dengue virus infection activates the IL-8 promoter and increases IL-8 mRNA 
levels. 
Our previous study established that DENV infection activates the IL-8 promoter 
and gene transcription within multiple cell types at three days post infection (Medin et 
al., 2005). Here, we provide confirmation of that data and further characterization of 
DENV-induced IL-8. We first examined the efficiency of DENV infection of HEK293A 
cells. Cells were either mock infected with C6/36 mosquito cell supernatant or infected 
with multiplicity of infections (MOIs) of 1 or 20 of concentrated DENV-2 NGC. 48 
hours post-infection, cells were stained with E-specific monoclonal antibody and 
analyzed by flow cytometry (Figure III-1A). We observed 16% infection with an MOI of 
1 and infection with an MOI of 20 demonstrated a maximum infection efficiency of 90% 
consistent with other researchers (A. Rothman, personal communication). There has been 
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some heterogeneity to the timing of DENV induced cytokine secretion. We verified our 
previous results within our system for the epithelial cell line HEK293A looking at 24, 48, 
and 72 hour time points for IL-8 promoter activation by luciferase assay (Figure III-1B). 
The earliest detection of dose dependent IL-8 promoter activation after was at 72 hours 
post infection. 72 hours post infection was the earliest we had previously observed IL-8 
secretion (Medin et al., 2005). We also wanted to verify activation of IL-8 mRNA 
production within these cells correlated with our luciferase results. We analyzed the 
effect of DENV infection on endogenous IL-8 mRNA production by TaqMan qRT-PCR 
(Figure III-1D). The IL-8 mRNA was standardized to the amount of β-actin, shown here 
relative to pcDNA (Figure III-1C). The first detection of endogenous IL-8 mRNA 
production was 5-fold at 48 hours, may due to distal elements present with the 
endogenous IL-8 promoter that are not present on the -133 bp IL-8 promoter driven 
luciferase plasmid (Figure III-1D). Matching the luciferase results, endogenous mRNA 
increased substantially at 72 hours post-infection. The delay of IL-8 induction after viral 
infection of HEK293A cells is consistent with our previous study (Medin et al., 2005) as 
well as others in HEK293 cells (Tsai et al., 2009). 
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Figure III-1: DENV infection activates the IL-8 promoter and IL-8 mRNA production. 
(A) DENV-2 infection efficiency of HEK293A cells. HEK293A cells were infected with 
DENV-2 were incubated for 48 hours, fixed and permeabilized, then probed with the 
anti-E-specific antibody 3h5. To detect 3h5 binding to E, anti-mouse antibody conjugated 
to FITC was used, and samples were analyzed by flow cytometry. (B) HEK293A cells 
were transfected with 40 ng of IL-8 promoter-driven firefly luciferase and 40 ng of 
herpes simplex virus thymidine kinase (HSV-TK) promoter-driven renilla luciferase 
plasmids using GeneJuice transfection reagent (Novagen). Cells for mock infection with 
C6/36 supernatant as the negative control and cells for DENV-2 infection were also 
C 
D 
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transfected with 100 ng of pcDNA plasmid. Cells for positive controls were transfected 
with 60 ng of pcDNA and 40 ng of a MyD88 adapter-like (MAL) protein expressing 
plasmid. 24 hours post-transfection, cells were mock infected with C6/36 cell supernatant 
or infected with DENV-2 at MOIs of 0.1, 1, and 2.5.  Luciferase activity of IL-8 
promoter driven luciferase was measured every 24 hours post-infection for 72 hours.  
Firefly luciferase activity was standardized to renilla luciferase activity as expressed by 
the constitutive HSV-TK promoter.  Results are representative of 3 assays. (C) and (D) 
HEK293A cells were transfected with pcDNA, a plasmid expressing MAL, or infected 
with DENV at an MOI of 1 for 24, 48, or 72 hours post-transfection or post-infection. 
Isolation of mRNA was performed using the RNeasy mini kit (QIAgen) and specific 
Taqman primers and probes for β-Actin mRNA (B) and IL-8 mRNA were used to 
quantitate mRNA. (D) IL-8 mRNA levels were standardized to β-Actin mRNA, 
presented as fold over pcDNA, and representative of 2 assays. 
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B. Expression of DENV prM-E, NS1G, NS4B or NS5 activates the IL-8 promoter. 
IL-8 has been shown to be almost ubiquitously expressed after DENV infection. 
Transcriptional regulation of IL-8 has been shown to differ between DENV infected 
HEK293A cells and DENV infected HepG2 cells (Medin and Rothman, 2006). This 
study also found differential effects of anti-inflammatory pharmaceuticals on IL-8 
secretion versus IL-8 transcriptional activation in DENV infected HEK293A cells and 
DENV infected HepG2 cells, suggesting there is a disconnect between DENV-induced 
signaling pathways that activate IL-8 promoter activation and IL-8 secretion. Further 
characterization of all proteins that can activate the IL-8 promoter could potentially 
explain cell type differences in IL-8 induction and pharmaceutical responsiveness. Thus, 
while our previous studies screened all the DENV proteins for activation of IL-8 protein 
expression, it remained likely that other proteins activated the IL-8 promoter without 
activating protein secretion. Preliminary experiments suggested this was possible with C. 
There was a precedent for the control of important cell signaling pathways by multiple 
DENV proteins, as was shown for the inhibition of IFN signaling (Muñoz-Jordan et al., 
2003; Ashour et al., 2009). While the importance of IL-8 to DENV infection is not clear, 
the large variety of cell types that express IL-8 in response to DENV infection suggest 
that IL-8 may have an unrecognized importance to DENV infection. Therefore, we 
surmised that other DENV proteins, when expressed alone, could activate the IL-8 
promoter and account for cell type specific differences in IL-8 induction without inducing 
IL-8 secretion.  
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Previously, our group had used DENV-2 NGC specific primers (Table III-1) to 
clone each of the ten individual DENV proteins (Figure III-2A). Further, we had two 
additional DENV expression constructs that were not included in our previous published 
studies. The first construct expresses prM (diagram shown in Figure III-2A; full sequence 
in Figure III-2B) and E (diagram shown in Figure III-2A; full sequence in Figure III-2B) 
together (prM-E) as they are natively produced in the viral polyprotein (diagram in 
Figure III-2A; full sequence in Figure III-2C).  In this configuration they are capable of 
producing virus-like particles (VLPs; Purdy and Chang, 2005).  The second additional 
plasmid construct contains the coding sequence for NS1 (diagram in Figure III-2A; full 
sequence in Figure III-2D) plus 26 amino acids from the NS2A region, which was 
reported to produce a GPI-linked variant of NS1, designated here as NS1G (Jacobs et al., 
2000; diagram in Figure III-2A; full sequence in Figure III-2E). Differences between 
DENV protein coding insert sequences and the documented DENV-2 NGC sequence 
(NCBI accession number M29095) are listed in Table III-2. 
We tested whether expression of any of our DENV protein expression constructs 
could activate the IL-8 promoter using dual luciferase assay (Figure III-3). Consistent 
with our earlier results, we observed dose-dependent activation of the IL-8 promoter by 
the plasmid expressing NS5. We also observed significant dose-dependent activation of 
the IL-8 promoter by the plasmids expressing prM-E, NS1G, and NS4B. To control for 
prM and E expressed from the same plasmid, prM-E, we also co-transfected plasmids 
expressing prM and E separately (prM + E). Other groups have demonstrated that prM-E 
but not prM + E, has the ability to produce VLPs (Purdy and Chang, 2005; Hsieh et al., 
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2008; Shang et al., 2012). Thus activation of the IL-8 promoter by prM-E may be due to 
the formation of VLPs. Induction of IL-8 mRNA and protein production by NS4B in the 
monocytic THP-1 cell line was recently described (Kelley et al., 2011). This induction 
was with full length NS4B and was found to be enhanced with NS2B-NS3 mediated 
cleavage of 2K from NS4B. Our NS4B construct contains only the carboxyl-terminal 112 
aa of NS4B, expressed in frame. This indicates that the carboxyl-terminal 112 aa region 
of NS4B is sufficient to activate transcription from the IL-8 promoter.  The amino-
terminal 136 aa were included in our NS4A construct, which did not show activation of 
the IL-8 promoter. While our preliminary data indicated dose-dependent activation of the 
IL-8 promoter by C and we do observe a trend towards dose-dependence, the results were 
not statistically significant. We further questioned whether NS1G and NS5 could also 
induce IL-8 promoter activation in a different epithelial cell type. Analysis of IL-8 
promoter induction by NS1, NS1G, and NS5 expression in HeLa cells showed that NS1G 
and NS5 induced IL-8 promoter activation while NS1 did not (Figure III-4). Overall, 
these data supports the hypothesis that there are multiple DENV proteins activating the 
IL-8 promoter. 
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Table III-1: Primers used to clone individual DENV proteins. 
C (forward) GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAATAACCAACGAA
AAAAGGCGAG 
C (reverse) GGGGACCACTTTGTACAAGAAAGCTGGGTCCGCCATCACTGTTGGAATCA
GC 
prM 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAGAACTGCAGGCA
TGATCATTATGCTGATTC 
prM 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCTATGTCATTGAAGGAGCGA
CAGCTG 
E (forward) GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAGAGCCCTGATTT
TCATCTTACTGACAG 
E (reverse) GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGGCCTGCACCATAACTC
CCAAATAC 
NS1 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAATTCACGCAGCA
CCTCACTG 
NS1 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCGGCTGTGACCAAGGAGTTGA
C 
NS1G 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCGGGTCCTGAGCATTTCTT
CCAG 
NS2A 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGGACATGGGCAGA
TTGACAACTTTTCA 
NS2A 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCTTTTCTTGTTGGTTCTTG
AAAGGGTTG 
NS2B 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAGCTGGCCACTAA
ATGAGGCTATCA 
NS2B 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCGTTGTTTCTTCACTTCCC
ACAG 
NS3 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCTGGAGTATTGT
GGGATGTCC 
NS3 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCTTTCTTCCAGCTGCAAACT
CCTTGAATT 
NS4A 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTCCCTGACCCTGA
ACCTAATCACA 
NS4A 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCTTTTCTGAGCTTCTCTGG
TTGCTTTTG 
NS4B 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCAGGAGCGGGCA
TCATGAAAA 
NS4B 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCTTCTCGTGTTGGTTGTGT
TCTTCAT 
NS5 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGGAACTGGCAACA
TAGGAGAGAC 
NS5 
(reverse) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCACAGGACTCCTGCCTCTT 
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All sequences except NS1G are from Medin et al., 2005. 
Normal text at the beginning of each primer are Gateway AttB recombination sites. 
Italicized sequences are Kozak initiation sequences. 
Underlined sequences are ATG start sites introduced for expression. 
Bold sequences are DENV-specific sequences. 
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Figure III-2: DENV proteins inserts and plasmids. 
(A) All DENV-2 NGC sequences were cloned by PCR from the DENV-2 infectious 
clone (Polo et al., 1997) and protein coding sequences were selected based on the 
annotation of that sequence (NCBI accession number M29095). Numerical notes 
designate the following. 1. C coding region (blue) included the carboxyl-terminal 
membrance anchor (green) encoded by nucleotides 401-438 bp. 2. Included in the prM 
and prM-E protein coding inserts is the 394-438 bp membrane insertion signal sequence 
(red). 3. 439-711 bp sequences denote the pr region of prM (green). 4. 889-936 bp encode 
the E protein membrane insertion sequence (red). 5. Sequence at 2338-2421 bp is the 
NS1 signal sequence (red), included in both NS1 and NS1G. 6. 6826-7233 bp encodes 
sequence of NS4B (purple) included in the NS4A DENV protein expressing plasmid due 
to an error in the notation of M29095. (B) – (F) Nucleotide and amino acid sequences of 
select DENV inserts illustrated in (A), with sequencing performed for Medin (2005) and 
Medin et al. (2005). Leader sequences are color coded red. Highlighted nucleotides and 
amino acids differ from the sequence documented in M29095. All differences in amino 
acid sequences are derived exclusively from the infectious clone template (Polo et al., 
1997) used to clone each DENV protein insert and has been previously documented. (B) 
The sequence of prM. (C) The sequence of E. (D) The sequence of prM-E. (E) The 
sequence of NS1. (F) The sequence of NS1G. Sequences in black are derived from 
NS2A. (G) Cloning plasmid (pDONR221; top) and expression plasmid (pDEST40; 
bottom). The backbone of pDONR221 includes pUC origin of replication for bacterial 
cell propagation, T1 and T2 transcription termination sequences, the kanamycin 
resistance gene for positive selection in bacteria, and M13 forward and reverse primer 
annealing sites flanking the cloning site. The cloning site includes attP1 and attP2 
recombination sites for directional cloning, the ccdB gene for negative selection of 
plasmids that have not undergone recombination, and the chloramphenicol resistance 
gene (Cm
R
) for positive counterselection. The pDEST40 plasmid backbone includes the 
pUC origin of replication, ampicillin and neomycin resistance genes, the f1origin of 
replication, the SV40 origin of replication, and SV40 polyadenylation (pA) sequence for 
G 
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the neomycin resistance gene expression. For expression of the gene insert, the CMV 
promoter is included as well as the T7 promoter for in vitro transcription initiation. 
Inserts lacking a stop codon have the V5 epitope and 6x histidine (His) tags followed by 
the bovine growth hormone (BGH) pA signal. Coding sequences are inserted by 
directional recombination mediated by the attR1 and attR2 sequences. The 
chloramphenicol resistance gene for positive selection of plasmid propagation and ccdB 
gene for negative selection of plasmids that have not undergone recombination are also 
included. Diagrams are adapted from the Gateway Technology manual (catalog numbers 
12281-010 and 12288-015; version F, 2004). 
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Table III-2: Summary of DENV insert nucleotide and amino acid sequence differences. 
Protein 
Nucleotide 
 
DENV-2 NGC
1
 
 
Infectious Clone
2
 
Expression 
Plasmid
3
 
 
Amino acid change 
E 
1075 
 
G 
 
A 
 
A 
 
E  K 
prM-E 
1056 
1075 
1644 
 
A 
G 
A 
 
A 
A 
A 
 
G 
A 
G 
 
(silent) 
E  K 
(silent) 
NS1 
3198 
 
C 
 
T 
 
T 
 
(silent) 
NS1 
3198 
 
C 
 
T 
 
T 
 
(silent) 
NS2A 
3876 
3744 
 
T 
T 
 
C 
C 
 
C 
C 
 
(silent) 
(silent) 
NS2B 
4428 
 
C 
 
T 
 
T 
 
(silent) 
NS3 
4545 
4932 
6177 
6317 
 
T 
G 
C 
A 
 
T 
T 
T 
G 
 
C 
T 
T 
G 
 
(silent) 
(silent) 
(silent) 
K  R 
NS4A 
6486 
 
A 
 
T 
 
T 
 
(silent) 
NS5 
8199 
8230 
8531-2 
8583 
8694 
10195 
10241 
 
T 
T 
GT 
A 
A 
A 
A 
 
C 
G 
TG 
G 
A 
T 
G 
 
C 
G 
TG 
G 
G 
T 
G 
 
(silent) 
L  V 
G  V 
(silent) 
(silent) 
N  Y 
K  R 
 
1. Sequence from NCBI accession number M29095. 
2. DENV-2 NGC infectious clone was published in Polo et al., 1997. 
3. All sequencing was performed by Carey Medin, PhD.  
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Figure III-3: Multiple DENV proteins activate the IL-8 promoter. 
HEK293A cells were transfected with 40, 80 or 100 ng of each DENV protein construct 
and luciferase plasmids with the Genejuice transfection reagent (Novagen). Cells 
transfected with 100 ng of pcDNA were the negative control. Cells transfected with 60 ng 
of pcDNA and 40 ng of a plasmid expressing MAL were the positive control. Cells were 
lysed and dual luciferase assay performed 24 hours post-transfection. Firefly luciferase 
activity was standardized to renilla luciferase activity driven by the constitutive HSV-TK 
promoter and are shown as fold over the negative control, pcDNA. Graph is the mean of 
all independent assays, with a minimum of 3 replicates per DENV construct with 
standard error of the mean (SEM). Statistical analysis, limited to the DENV constructs, 
was by 2-way ANOVA comparing both construct and dosage with the Bonferroni post 
test comparing between all dosages. (*) p < 0.01, (**) p < 0.0001 between indicated 
dosages. 
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Figure III-4: Activation of the IL-8 promoter by NS1G and NS5 in HeLa cells. 
HeLa cells were transfected with 40, 80, and 100 ng of NS1, NS1G, or NS5 and 
luciferase plasmids. Cells transfected with 100 ng of pcDNA were the negative control. 
Cells transfected with 60 ng of pcDNA and 40 ng of a plasmid expressing MAL were the 
positive control. Cells were lysed and dual luciferase assay performed 24 hours post-
transfection. Firefly luciferase activity was standardized to renilla luciferase activity 
expressed by the constitutive HSV-TK promoter and set as fold over the negative control, 
pcDNA. Statistical analysis was by t test and (*) represents p < 0.05. Graph is the mean 
of 2 independent assays. 
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C. Expression of DENV proteins 
We had previously attempted to measure expression levels of DENV protein with 
limited success. Our previous study used a lacZ plasmid as a transfection control and 
determined 40% transfection efficiency (Medin et al., 2005). Here, we determined 
optimal transfection efficiencies in HEK293A cells using both the Gateway positive 
control of chloramphenicol acetyltransferase (CAT) tagged with enhanced green 
fluorescent protein (eGFP) control plasmid (as well as a smaller (3.2 Kb) pmaxGFP, 
expressing only eGFP (Figure III-5A). We observed that a micrograms DNA to 
microliters Lipofectamine 2000 ratio of 1:4 provided optimal transfection efficiency 
(Figure III-5B). However, while we were able to obtain 99% transfection efficiency with 
the smaller pmaxGFP plasmid, we were only able to obtain 56% transfection efficiency 
with the Gateway control CAT-tagged eGFP plasmid (Figure III-5B). To look directly at 
expression efficiency of DENV plasmid constructs, we took advantage of the Gateway 
system and transferred the DENV protein coding sequences into a vector containing 
carboxyl-terminal eGFP tag (Figure III-6A). Plasmids containing the protein coding 
sequences for DENV NS3 and NS5 were transfected alone or cotransfected with LacZ 
into HEK293A cells, then assessed for eGFP expression by fluorescent microscopy 
(Figure III-6B). We observed substantial background fluorescence, most likely due to cell 
death as indicated by cells being smaller, rounded up, and often clumped (Figure III-6B, 
overlay images on right). Therefore, we turned again to flow cytometry, a more stringent 
and quantitative analysis. Plasmids containing the protein coding sequences for DENV 
NS1, NS1G, NS3, and NS5 tagged with eGFP were transfected into HEK293A cells 
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using optimal transfection conditions (Figure III-5B) and eGFP expression was quantified 
by flow cytometry analysis 48 hours post-transfection (Figure III-7). We saw that the 
expression of DENV proteins varied, predominantly correlating with plasmid size. The 
exception to this correlation of decreased fluorescence with increased plasmid size was 
NS1G. The difference in NS1G expression was most likely due to the use of trypsin 
required for analysis of HEK293A cells by flow cytometry. Variation in expression 
according to plasmid size also correlated with what we observed with the control 
plasmids. The larger CAT-conjugated eGFP plasmid had reduced eGFP expression as 
compared to the smaller pmaxGFP plasmid (Figure III-5B). We conclude that, while 
transfection efficiency in this study was improved over our previous study, overall 
expression of DENV proteins was low and decreased with increasing plasmid size. 
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Figure III-5: Test of transfection efficiency with eGFP expressing plasmids. 
(A) Schematic diagrams of control plasmids. pCAT-GFP (pcDNA/GW-47/CAT) is a 
positive control plasmid provided with the Gateway pDEST47 eGFP expression vector 
(Invitrogen). This plasmid includes the pUC origin, the ampicillin resistance gene for 
positive selection during bacterial propagation of the vector, CMV promoter driven 
expression of chloramphenicol acetyltransferase (CAT) with a carboxyl-terminal eGFP 
tag and the bovine growth hormone (BGH) poly-adenosine addition sequence (pA). In 
addition, pCAT-GFP includes the attB recombination sites, F1 origin of replication, 
SV40 origin of replication and the neomycin resistance gene with the SV40 pA for 
positive selection in eukaryotic cells. pmaxGFP is an eGFP positive transfection control 
(Lonza) which includes pUC, kanamycin resistance gene for positive selection during 
bacterial propagation of the vector as well as CMV promoter-driven expression of eGFP 
A 
B 
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with the SV40 pA. (B) Transfection efficiency was optimized using varying ratios of 
micrograms of DNA to microliters of the Lipofectamine 2000 transfection reagent with 
either pmaxGFP plasmid or the Invitrogen Gateway CAT-eGFP plasmid. 48 hours post 
transfection, cells were fixed and permeabilized then assessed for eGFP expression by 
flow cytometry.  
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Figure III-6: Expression of DENV NS3 and NS5 proteins fused to eGFP. 
(A) DENV protein coding sequences for NS1, NS1G, NS3, and NS5 in the pDONR221 
cloning vector were introduced into the pDEST47 vector by the LR recombination 
reaction of the Gateway system. The recombination reaction replaced the ccdB death 
domain with the DENV protein coding sequence. Plasmids were then transformed into E. 
coli, propagated under ampicillin selection, and purified by endotoxin free maxiprep kit 
(QIAgen). (B) HEK293A cells in 6-well plates were transfected using Lipofectamine 
2000 (Invitrogen) with a combination of pcDNA and LacZ, NS3, NS3 and LacZ, NS5, or 
NS5 and LacZ. Cells were visualized 48 hours post transfection on an EVOS fl model 
fluorescent microscope (Advanced Microscopy Group; AMG). Image corrections were 
applied to all samples equally on the microscope during visualization and image capture. 
Images representative of each plate are presented from left to right as epi light image of 
all cells, GFP visualization, and an overlay of the two images. Cells with predominant 
fluorescence were smaller, rounded up, and separated from the plate often in clumps 
indicating background fluorescence due in dead or dying cells.  
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Figure III-7: Expression of DENV proteins NS1, NS1G, NS3 and NS5 conjugated to eGFP. 
HEK293A cells were transfected with a negative control pcDNA plasmid, the positive 
control pCAT-eGFP, or plasmids expressing DENV proteins NS1, NS1G, NS3, and NS5 
tagged with eGFP. 48 hours post transfection, cells were trypsinized, fixed, and 
permeabilized prior to flow cytometry analysis. Results are presented as the percent of 
live cells expressing eGFP and are the mean of 3 experiments. 
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D. Analysis of IL-8 induced by individual DENV proteins 
Our previous work identified and characterized NS5 as the only DENV protein 
that induced IL-8 secretion (Medin et al., 2005). However, we identified NS1G, prM-E, 
and NS4B as well as NS5 as being able to induce IL-8 promoter-mediated transcription 
(Figure III-3). With the improved transfection efficiency as compared to our last study 
(Figure III-5) as well as the additional prM-E and NS1G plasmids, we attempted to 
determine which DENV proteins induced IL-8 mRNA production (Figure III-8B) and IL-
8 secretion (Figure III-8C). HEK293A cells were transfected with each DENV construct, 
supernatants collected at 24 and 48 hours post-transfection, and mRNA collected at 48 
hours post-transfection. Different from our previous study, we also included cells 
transfected with pcDNA as a negative control. IL-8 mRNA was standardized to β-actin 
mRNA or GAPDH mRNA (Figure III-8A). GAPDH mRNA was both more abundant and 
demonstrated steadier levels between samples as compared to levels of β-actin mRNA 
(Figure III-8A). However, standardization of IL-8 mRNA to GAPDH mRNA did not 
show expected and previously demonstrated relative increases in IL-8 mRNA in samples 
transfected with MAL, the positive control, nor NS5 (Figure III-8B). Standardization of 
IL-8 mRNA to β-actin mRNA demonstrated relative increases in IL-8 mRNA in samples 
transfected with either MAL, the positive control, and NS5 (Figure III-8B), as previously 
shown (Medin et al., 2005). We did observe a consistent trend of increased IL-8 mRNA 
in cells transfected with NS1G as compared to cells transfected with NS1 (Figure III-8B). 
However, the increase in IL-8 mRNA in cells transfected with NS1G was not significant 
as compared to either pcDNA or other DENV proteins.  
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We also examined IL-8 secretion in supernatants of cells transfected with each 
DENV protein construct using IL-8 ELISA. At 24 hours post transfection, we observed 
little to no secretion of IL-8. Initially, there appeared to be some induction of IL-8 
secretion by E, NS1G, NS2A, NS4B and NS5 at 48 hours post transfection. We also 
observed increased IL-8 induction in supernatants of cells transfected with NS1G as 
compared to NS1. However, levels of IL-8 protein in supernatants were not significantly 
different (P > 0.05 by one-way ANOVA for group analysis and unpaired t test of each 
DENV construct to pcDNA transfected cell supernatants, the negative control). The 
background IL-8 secretion from pcDNA transfected cell supernatants at 48 hours post-
transfection is greater than background from our previous study (Medin et al., 2005). 
Thus, improved transfection efficiency may be increasing background IL-8 secretion, 
complicating analysis. 
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Figure III-8: IL-8 production induced by DENV proteins. 
HEK293A cells transfected with each DENV protein construct were lysed 24 hours post-
transfection and mRNA extracted using the RNeasy mini kit (QIAgen). RNA samples 
were subjected to multiplexed two-step quantitative RT-PCR using the TaqMan two-step 
cDNA synthesis kit (Applied Biosystems) and 20x primer and probe mixes for β-actin 
mRNA, GAPDH mRNA, and IL-8 mRNA. Quantitation was performed over 40 PCR 
cycles. (A) Average cycle threshold (Ct) values of β-actin mRNA and GAPDH mRNA, 
the endogenous controls for experiments in (B), are presented. (B) Levels of IL-8 mRNA 
standardized either to β-actin mRNA or GAPDH mRNA are presented as relative to 
pcDNA, the negative control. Data presented are the mean of 3 independent experiments. 
(C) HEK293A cells were transfected with each DENV protein expression plasmid and 
cell supernatants were collected at 24 and 48 hours post transfection. IL-8 secretion was 
measured by IL-8 ELISA. Results were tested by both group analysis (one-way ANOVA) 
and pair analysis (supernatants of cells transfected with each DENV protein expression 
plasmid compared by t-test to cell supernatants of cell transfected with pcDNA, the 
negative control). No significant differences (p < 0.05) were found. Results are the mean 
of 5 independent experiments.  
C 
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E. DENV NS5 expression induces promoter activation and mRNA transcription of 
other cytokines 
The IL-8 promoter contains binding sites for the transcription factors AP-1, 
C/EBP, and NF-κB. These transcription factors regulate a variety of other cytokines, 
including many involved in inflammation. We further questioned whether NS5 could 
activate other promoters regulated similarly to IL-8. The RANTES promoter contains 
binding sites for all three of these transcription factors (Greaves and Gordon, 2002) and 
DENV has been shown to induce RANTES expression from hepatocytes (Lin et al., 
2000; Conceição et al., 2010), endothelial cells (Avirutnan et al., 1998), monocytes (Chen 
and Wang, 2002), and macrophages (Chen and Wang, 2002). We had not detected 
activation of the RANTES promoter by NS5 in the earlier study (Medin et al., 2005).  On 
re-testing, however, we found significant activation of a RANTES reporter plasmid by 
NS5 (Figure III-9).  This discrepancy may reflect improved transfection efficiency since 
the original study (Figure III-5).  This data provides evidence that NS5 activates other 
promoters regulated by the transcription factors AP-1, C/EBP, and NF-κB that also 
regulate IL-8. 
To examine other possible targets regulated by AP-1, C/EBP, and NF-κB, we 
used a PCR array to examine the effect of NS5 expression on transcription of a broad 
range of cytokines. This pre-made array lacked RANTES but included IL-8 as well as a 
number of other genes regulated by AP-1, C/EBP, or NF-κB including IL-1, IL-6, TNFα, 
VEGF, and GM-CSF.  Of the 86 genes examined, only TNFα contained binding sites for 
AP-1, C/EBP, and NF-κB and was significantly upregulated (Table III-3).  We verified 
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increased endogenous TNFα mRNA production by NS5 using TaqMan qRT-PCR (Figure 
III-10A). The only other gene we observed significantly upregulated by transfection with 
NS5 was Inhibin βA (Table III-3). Inhibin-βA (INHβA) forms a homodimer called 
activin A, a follicle stimulating hormone (FSH) secretion stimulating factor. Activin A is 
stimulated by TNFα and has been shown to cause cell cycle arrest and apoptosis in in B 
cells while having both stimulatory and inhibitory effects on T cells (Reviewed in Shav-
Tal and Zipori, 2002). While potentially interesting, there is no known association of 
activin A or INHβA with DENV. However, TNFα has a clear association with severe 
dengue and is clinically relevant.  
In addition to validating TNFα mRNA expression, we also measured TNFα 
protein secretion. No TNFα was detected in the supernatants of HEK293A cells 
transfected NS5 or any other DENV construct as measured by ELISA (Figure III-10B). 
This data demonstrates that NS5 activates TNFα mRNA production, another gene 
regulated by the transcription factors AP-1, C/EBP, and NF-κB that regulate IL-8. 
Therefore, NS5 appears to contribute to the activation of multiple inflammatory cytokines 
important to DENV infection. 
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Figure III-9: NS5 activates the RANTES promoter. 
HEK293A cells were transfected with 40, 80, and 100 ng of NS1 or NS5 and luciferase 
plasmids. Cells transfected with 100 ng of pcDNA were the negative control. Cells 
transfected with 60 ng of pcDNA and 40 ng of a plasmid expressing MAL were the 
positive control. Cells were lysed and dual luciferase assay performed 24 hours post-
transfection. Firefly luciferase activity was standardized to renilla luciferase activity 
expressed by the constitutive HSV-TK promoter and set as fold over the negative control, 
pcDNA. Statistical analysis was by t test and (*) represents p < 0.05. Graph is the mean 
of 3 independent assays. 
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Gene Fold Up- or Down-
Regulation 
Major Function
1
 
IL-8 12 Chemoattractant for cells expressing CXCR1 and 
CXCR2 
TNF 4 Inflammatory mediator, endothelial activation 
INHβA 5.3 FSH stimulating factor, B cell cycle arrest & 
apoptosis 
LTα -2.5 Killing, endothelial activation 
IL-16 -2.5 Chemoattractant for CD4 T cells, monocytes, and 
eosinphils; anti-apoptotic for IL-2 stimulated cells 
IL-6 -1 T and B cell growth and differentiation factor, 
fever 
IL-1β -1.8 Cell proliferation, differentiation, and apoptosis 
IFNβ1 1.3 Antiviral, upregulation of MHC 
GAPDH -1.1 Carbohydrate metabolism 
ACTB -1.2 Cell motility, structure, and integrity 
 
1. From Pubmed Gene and Janeway et al., 2001.   
Table III-3: Selection of genes identified by PCR array as upregulated or downregulated by DENV NS5 
expression. 
103 
 
 
R
e
la
ti
v
e
 Q
u
a
n
ti
ty
 m
R
N
A
(f
o
ld
 o
v
e
r 
p
c
D
N
A
)
pc
D
N
A
M
A
L
N
S5
0
5
10
15
20
100
350
600
IL-8
TNF
 
T
N
F

 (
p
g
/m
L
)
pc
D
N
A
M
A
L C
pr
M E
N
S1
N
S1
G
N
S2
A
N
S2
B
N
S3
N
S4
A
N
S4
B
N
S5
0
100
200
300
 
Figure III-10: NS5 activates TNFα mRNA production. 
(A) HEK293A cells were transfected with pcDNA, MAL or NS5, lysed 24 hours post-
transfection, and total RNA isolation was performed with the QIAgen RNeasy mini kit. 
TaqMan quantitative RT-PCR analysis was performed with primers and probes specific 
to IL-8 and TNFα mRNA. Results have been normalized to β-Actin mRNA, are 
presented relative to pcDNA, and are representative of 3 independent assays. (B) 
HEK293A cells were transfected with each DENV construct. Supernatants were collected 
at 48 hours post transfection and probed for secreted TNFα by the TNFα-specific DuoSet 
ELISA (R&D Systems). Data presented is the mean of 2 independent experiments.  
A 
B 
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F. The polymerase domain, but not polymerase function, is required for NS5-induced 
IL-8 secretion 
During the course of this study, we attempted to further analyze NS5-mediated 
IL-8 secretion by generating mutations and truncations of NS5. Our early attempts were 
based on the hypothesis of NS5 NLS being a linker region between the methyltransferase 
and polymerase domains (Forwood et al., 1999; Brooks et al., 2002; Figure III-11A). In 
these initial experiments, neither the amino- nor carboxyl-terminal constructs 
demonstrated any activation of the IL-8 promoter. We made a second attempt to clone the 
polymerase domain after the publication of the crystal structure of the DENV-3 NS5 
polymerase (Yap et al., 2007), demonstrating that the NLSs were integral parts of the 
NS5 polymerase domain (Figure III-11A). We generated a new NS5 truncation from aa 
269 to 900 (NS5-270C; Table III-4; diagram in Figure III-11A; full sequence in Figure 
III-11E) based on sequence alignment with the DENV-3 polymerase domain, as 
described by Yap et al. (2007). Additionally, we also generated point mutations in NS5 
converting the GDD polymerase active motif to non-functional GAA (Table III-5; 
Diagram in Figure III-11A; full sequence in Figure III-11F). Initial screens looking at 
activation of the IL-8 promoter were encouraging, but given the potential disconnect 
between IL-8 promoter activation and secretion (above and Medin and Rothman, 2006) 
we were particularly interested in comparing IL-8 secretion between these NS5 
constructs. Hence, we looked at IL-8 secretion by ELISA (Figure III-12). As shown, the 
amino-terminal 313 (NS5-N320) or 368 (NS5-N368) aa (Table III-4; diagrams in Figure 
III-11A, full sequences in Figure III-11B and Figure III-11C), containing the 
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methyltransferase domain and either no NLS or the bNLS, did not induce IL-8.  
However, the polymerase domain, NS5-270C, including both NLSs, induced IL-8 
secretion comparable to wild type NS5, as did our GAA polymerase-mutated NS5 (NS5-
PolMt). Thus, while polymerase function is dispensable to NS5 induced IL-8 secretion, 
the polymerase domain is sufficient. 
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Table III-4: NS5 truncations primers. 
NS5-N320 
(reverse) 
GGGACCACTTTGTACAAGAAAGCTGGGTCCTATCCAGTTTGTTTTGTTTCA
TAGCTGCCATG 
NS5-N368 
(reverse) 
GGGACCACTTTGTACAAGAAAGCTGGGTCCTATTCTTTCGGTTCTTGGGTT
CTCGTGT 
NS5-270C 
(forward) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGAGATACCAAACCT
AGACATAATCG 
 
 
Table III-5: NS5 PolMt site-directed mutagenesis primer. 
wild type sequence ggccatcagtggagatgattgtgttgtgaaacc 
NS5-PolMt  
5’  3’ primer 
ggccatcagtggagctgcttgtgttgtgaaacc 
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Figure III-11: Diagrams and sequences of NS5 constructs. 
(A) Schematic representation of NS5, NS5 truncations, and NS5 polymerase mutant. Key 
structural features of NS5 are shown. The amino-terminal third of NS5 contains the 
methyltransferase function (purple). The remaining carboxyl-terminal two-thirds of NS5 
constitutes the polymerase domain (blue) and contains both NLSes. The bNLS, between 
amino acids 320 and 368, also contains the NES (yellow). The abNLS is between amino 
acids 369 to 405. The polymerase GDD active motif is marked at amino acids 653-655. 
The full sequence of NS5 is shown (B). Nucleotide and amino acid sequence differences 
from the standard DENV-2 NGC sequence (NCBI accession number M29095) are 
highlighted and listed in Table III-2. The truncation NS5-N320 is shown schematically in 
(A) and the full sequence is shown in (C). NS5-N320 contains the amino-terminal 313 
amino acids, includes the full methyltransferase domain and a small portion of the 
polymerase domain, but lacks both NLSes. The truncation NS5-N368 is shown 
schematically in (A) and the full sequence is shown in (D). NS5-N368 contains the 
amino-terminal 368 amino acids and includes the full methyltransferase domain and a 
small portion of the polymerase domain. NS5-N368 contains the bNLS and NES, but 
lacks the abNLS. The truncation NS5-270C is shown schematically in (A) and the full 
sequence is shown in (E). NS5-270C contains the carboxyl-terminal 631 amino acids. 
This region was identified by sequence alignment with the DENV-3 sequence used to 
crystallize the DENV polymerase domain (Yap et al., 2007). NS5-270 contains the entire 
polymerase domain and includes both NLSes. The NS5-PolMt is shown schematically in 
(A) and the full sequence is shown in (F). NS5-PolMt contains a non-functional 
polymerase motif generated by site directed mutagenesis changing the essential GDD to 
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GAA. Nucleotide and amino acid changes generated by site directed mutagenesis are 
highlighted in blue. NS5-PolMt contains no other changes to the standard NS5 sequence. 
Primers used to generate truncations are shown in Table III-4. The sense primer used for 
site directed mutagenesis to generate NS5-PolMt is shown in Table III-5. All nucleotide 
sequences were verified by full length DNA sequence analysis and were expressed using 
the pDEST40 (Figure III-2G).  
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Figure III-12: The polymerase domain, but not function, is required for NS5 induced IL-8 secretion. 
HEK293A cells were transfected with pcDNA as the negative control, NS5, NS5-N320, 
NS5-N368, NS5-270C, or NS5-PolMt using Lipofectamine 2000. IL-8 secretion was 
measured 24 and 48 hours post transfection in cell supernatants by IL-8 Duo-Set ELISA 
development kit (R&D Systems). Results are the average of 3 independent assays. 
Statistical analysis was performed by t-test. 
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Summary of Aim 1 
The goal of this aim was to examine the activation of the IL-8 promoter by DENV 
infection and expression of DENV proteins addressing these questions with the following 
answers: 
Does expression of DENV proteins other than NS5 activate IL-8 transcription? 
We found that transfection with prM-E, NS1G, and NS4B, as well as NS5 
activated IL-8 promoter-driven transcription 24 hours post-transfection. 
Does expression of NS5 activate transcription of other cytokines? 
We found that NS5 induced transcription from a RANTES promoter 24 hours 
post-transfection, as well as induced TNFα mRNA 24 hours post-transfection, both of 
which are also regulated by AP-1, C/EBP, and NF-κB. Other cytokines found to be 
upregulated by NS5 expression in epithelial cells were not regulated by these 
transcription factors and play no known roles during DENV infection. 
What regions of NS5 are important to NS5 driven IL-8 promoter activation? 
Our results indicate that the polymerase domain was sufficient to induce IL-8 
secretion but that polymerase function was not required. 
In addition, this aim has demonstrated that, while the IL-8 promoter and IL-8 
mRNA production is not induced until 72 hours post infection, transfection with prM-E, 
NS1G, NS4B, or NS5 induces IL-8 promoter activation 24 hours post transfection. The 
interpretation and significance of these observations are discussed further in Chapter IV. 
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Aim 2 
The second aim of this work characterized the activation of transcription factors AP-
1, C/EBP, and NF-κB within the IL-8 promoter by DENV proteins. These studies 
addressed the following questions: 
 Does activation of the IL-8 promoter by DENV proteins depend on any single 
transcription factor? 
 What individual transcription factors are activated by DENV proteins?  
 
G. AP-1 is activated by expression of prM-E, NS1G and NS5. 
In the first aim, we observed that DENV proteins prM-E, NS1G, NS4B, and NS5 
activated the IL-8 promoter (Figure III-3), even though we had previously observed that 
only NS5 induced IL-8 secretion (Medin et al., 2005). These data indicate that DENV 
may have multiple mechanisms to induce IL-8. To further examine the promoter 
activation of IL-8 by DENV proteins, we next looked at the activation of individual 
transcription factors AP-1, C/EBP, and NF-κB by each of the DENV proteins (Figure 
III-13).  To measure the activation of individual transcription factors, we used luciferase 
reporter plasmids driven by tandem repeats of binding sites for AP-1, C/EBP, and NF-κB 
(Figure II-1). As seen previously (Medin et al., 2005), expression of NS5 activated AP-1-
driven luciferase expression (Figure III-13A).  Consistent with their ability to activate the 
IL-8 promoter, prM-E and NS1G also significantly activated AP-1 driven luciferase 
expression in a dose dependent manner. While not statistically significant, C and NS4B 
both showed a trend of increasing AP-1-driven luciferase expression with increasing 
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dosages.  Thus, the DENV proteins that activated the IL-8 promoter correlated well with 
the DENV proteins that activated an AP-1 driven reporter. 
The overall activation of the C/EBP-driven luciferase promoter was very low 
(Figure III-13B). A comparison of all DENV constructs and dosages by 2-way ANOVA 
demonstrated that while activation of C/EBP depended on which DENV protein was 
expressed, it did not depend on the dosage of plasmid. One possible explanation for this 
was that we had reached a threshold for activation. If we had reached a threshold of 
activation, the Bonferroni post-test would not determine which plasmids were significant. 
Therefore, we compared each sample against pcDNA, the null hypothesis, by t test. 
Consistent with our previous report, by t test we saw that all doses of NS5 significantly 
induced C/EBP-driven luciferase expression. Of the other DENV expression constructs 
that induced activation of the IL-8 promoter, only prM-E significantly activated C/EBP-
driven luciferase expression. In addition, we found that C, prM, and E also had 
statistically significant activation of C/EBP-driven luciferase expression (Figure III-13B).  
Luciferase expression driven by NF-κB was also low with all DENV expression 
plasmids (Figure III-13C). NF-κB-driven luciferase expression did depend both on the 
DENV protein expressed and the dosage, however there was no significant interaction 
between the two. Again, we tested each individual sample against pcDNA, the null 
hypothesis, by t test. Similar to our previous study, we saw that NS5 induced a modest 
increase in NF-κB, which was statistically significant. Of the other DENV expression 
constructs that induced activation of the IL-8 promoter, only NS1G and prM-E showed 
statistically significant activation and that effect only occurred at higher doses. In 
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addition, C and E expressing constructs, which did not induce IL-8 promoter activation, 
modestly but significantly activated NF-κB-driven luciferase expression at all doses 
(Figure III-13C).   
A summary and comparison of the statistical analysis is presented in Table III-6. 
While we are cautious to interpret the results with C/EBP- and NF-κB-driven luciferase 
reporters, our results with NS5 are consistent with our previous study (Medin et al., 
2005). 
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Figure III-13: Activation of AP-1, C/EBP, and NF-κB driven luciferase expression by DENV constructs. 
Luciferase expression was measured in HEK293A cells transfected with luciferase 
expression plasmids driven by tandem repeats of consensus AP-1 (A), C/EBP (B), and 
NF-κB (C) driven luciferase plasmids. HEK293A cells were transfected with 40, 80, and 
100 ng of each DENV expression construct and luciferase plasmids. Cells transfected 
with 100 ng of pcDNA were the negative control. Cells were lysed and dual luciferase 
assay performed 24 hours post-transfection. Firefly luciferase activity was standardized 
to renilla luciferase activity as expressed by the constitutive HSV-TK promoter and set as 
fold over the negative control, pcDNA. Graphs shown are the mean of at least three 
independent assays for each DENV construct. Statistical analysis was by 2 way ANOVA 
with Bonferroni post test.  (B) and (C) were additionally analyzed by t test, comparing to 
the set value 1 fold induction. In (A) (*) represents p < 0.05; (**) represents p < 0.0001. 
In (B) and (C) (*) represents p < 0.05; (**) represents p < 0.005. Graphs are the mean of 
at least 3 independent assays. 
  
122 
 
 
Table III-6: Statistical summary of AP-1, C/EBP, and NF-κB luciferase reporters. 
DENV expression 
construct 
AP-1 C/EBP NF-κB 
C ns * * 
prM ns ** ns 
E ns * * 
prM + E ns ns ns 
prM-E *** * *
1
 
NS1 ns ns ns 
NS1G * ns *
2
 
NS2A ns ns ns 
NS2B ns ns ns 
NS3 ns ns ns 
NS4A ns ns ns 
NS4B ns ns ns 
NS5 *** ** ** 
 
* p < 0.05 
** p < 0.005 
*** p < 0.001 
1. Significant at 100 ng dose. 
2. Significant at 80 and 100 ng doses.  
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H. Activation of the IL-8 promoter by expression of DENV proteins does not depend 
on any single transcription factor. 
Previously, we observed that activation of the IL-8 promoter by NS5 was 
increased when the AP-1 binding site was mutated and modestly decreased when either 
the C/EBP or NF-κB binding sites were mutated, but did not depend on any single 
transcription factor (Medin et al., 2005). Since our data also showed activation of the IL-
8 promoter by prM-E, NS1G, and NS4B (Figure III-3), we sought to determine the 
dependence of IL-8 promoter activation on AP-1, C/EBP, and NF-κB.  We used IL-8 
promoter-driven luciferase plasmids mutated at specific binding sites for AP-1 (Figure 
III-14A), C/EBP (Figure III-14B), and NF-κB (Figure III-14C), as described in our 
earlier study (Figure II-1).  Consistent with our previous study focusing on NS5 (Medin 
et al., 2005), we observed a significant increase in DENV NS5-induced luciferase 
expression from the IL-8 promoter mutated at the AP-1 site, and a similar trend was 
observed with expression of NS1G, and NS4B, but was only statistically significant for 
prM-E.  There was no significant decrease in activation of the IL-8 promoters mutated at 
the C/EBP or NF-κB sites in response to expression of NS5, nor did mutations in C/EBP 
or NF-κB affect promoter activation by prM-E, NS1G, or NS4B.  These results indicate 
that there is no dependence on any single transcription factor for activation of the IL-8 
promoter by any of the DENV proteins.  
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Figure III-14: Activation of the IL-8 promoter does not depend on any single transcription factor. 
Wild type IL-8 promoter activation was compared to activation of mutant IL-8 promoters 
preventing binding of the individual transcription factors AP-1 (A), C/EBP (B), or NF-κB 
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(C). HEK293A cells were transfected with 100 ng of prM-E, NS1G, NS4B, or NS5 and 
luciferase plasmids. Cells transfected with 100 ng of pcDNA were the negative control. 
Induction of the IL-8 luciferase reporter plasmid was the positive control. Cells were 
lysed and dual luciferase assay performed 24 hours post-transfection. Firefly luciferase 
activity was standardized to renilla luciferase activity as expressed by the constitutive 
HSV-TK promoter and set as fold over the negative control, pcDNA.  Graphs shown are 
the mean of at least 3 independent assays for each DENV construct.  Statistical analysis 
was by 2 way ANOVA comparing each DENV construct and IL-8 to each mutant IL-8 
promoter.  Bonferroni post test and Wilcoxon matched pairs signed rank test was also 
performed. (*) p < 0.01, (**) p < 0.001. 
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I. Inhibitory subunits Fra-1 and Fra-2 of AP-1 are not differentially activated during 
DENV infection 
There was significant activation of AP-1 by all DENV proteins that activate IL-8 
transcription (Figure III-13A). However, mutation of the AP-1 site within the IL-8 
promoter significantly increased transcription and luciferase expression (Figure III-14A). 
Similar luciferase results were seen in monocytes after LPS stimulation using the same 
mutant IL-8 luciferase plasmid (Gray and Pestka, 2007). In that study, the authors used 
PROMO, a web-based transcription factor binding site predictor to analyze the sequence 
of the mutated AP-1 binding site sequence generated in the IL-8 promoter (Okamoto et 
al., 1994). The authors reported that the mutation of the AP-1 site resulted in the 
inadvertent creation of a consensus binding site for TFIIB, a constitutively active 
transcription factor. We repeated that analysis and did not see the TFIIB binding 
sequence when binding sequences were limited for human transcription factor binding 
sites.  By PROMO, the mutation of the AP-1 binding site in the IL-8 promoter did 
generate two novel overlapping GATA-1 sites (Figure III-15). However, GATA-1 is 
specific for monocytic cells and has not been reported to be expressed in HEK293 cells. 
In addition to PROMO, we also used the other web-based transcription factor binding site 
prediction software TFSEARCH, TFBIND and JASPAR to predict potential transcription 
factors binding the mutated AP-1 binding site on the IL-8 promoter. TFSEARCH found 
potential GATA-2 binding sites, TFBIND also found GATA-1, and JASPAR found 
GATA-2 and GATA-3. No other prediction algorithm found a potential TFIIB binding 
site generated by mutation of the AP-1 binding site in the IL-8 promoter. Thus, the 
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hypothesis that a TFIIB binding site had been generated in the IL-8 promoter mutated at 
the AP-1 binding site does not appear to adequately explain our results in Figure III-14A. 
Based on these analyses, we considered alternative theories for DENV protein-induced 
increased IL-8 promoter activation when the AP-1 binding site is mutated. 
 Regulation of IL-8 secretion by NS5 was previously proposed to explain why 
mutation of the NS5 NLS increased IL-8 secretion (Pryor et al., 2007) based on the 
observation in HCV that IL-8 may have both pro- and anti-viral effects (Koo et al., 2006). 
In Figure III-13A, we observed consistent activation of an AP-1-driven luciferase 
promoter. Our data in Figure III-14A, indicated that AP-1 may have an inhibitory as well 
as an activating effect on IL-8 promoter activation. Consistent with the proposal by Pryor 
et al. (2007) that NS5 modulates IL-8 activation, modulation of AP-1 activating and 
inhibitory activity is one potential mechanism. AP-1 is a homo- or hetero-dimer of 
members of Jun family proteins with members of Fos and ATF family members. Fos 
family members Fra-1 and Fra-2 have both been shown to be inhibitory in certain 
systems (McCarty, 1998; Adiseshaiah et al., 2006). Here, we examined Fra-1, and Fra-2 
binding to the IL-8 promoter following DENV infection. The positive AP-1 component 
c-Jun was previously shown to be induced early after DENV infection (Ceballos-Olvera 
et al., 2010) and examined here as a positive control. To observe activated c-Jun, Fra-1, 
and Fra-2, we used the Miltenyi FactorFinder kit. Streptravidin-conjugated -133 bp of the 
IL-8 promoter was bound to µMACS beads and incubated with lysates of DENV- or 
mock-infected cells harvested at 0, 6, 24, 48, and 72 hours post-infection. Our results did 
not show any difference in AP-1 subcomponents c-Jun, Fra-1, or Fra-2 bound to the IL-8 
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promoter between mock and DENV infected cells. While this data demonstrates that Fra-
1 and Fra-2 are not involved in the negative regulation of IL-8 in HEK293A cells, other 
AP-1 subunits may still be involved in modulation of the IL-8 promoter. 
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Figure III-15: Predicted transcription factors binding the AP-1 and mutated AP-1 sites of the IL-8 promoter by 
PROMO prediction software. 
Predicted transcription factor binding sites for the wild type IL-8 promoter (top) were 
compared to the IL-8 promoter mutated at the AP-1 binding site (below) using the web-
based PROMO prediction software. Mutated nucleotides are underlined first (black, thin). 
The predicted AP-1 binding sequence is underlined next (black, bold). Transcription 
factors other than AP-1 are shown in color, bold. A predicted XBP-1 site is shown in 
purple. Overlapping GATA-1 sites are shown in green. 
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Figure III-16: Sub-components of AP-1 that can bind the IL-8 promoter after DENV or mock infection. 
HEK293A cells were either mock infected with C6/36 supernatant or infected with 
DENV-2 strain NGC for 0, 6, 24, 48, or 72 hours post-infection. Cell lysates were 
incubated with µMACS beads conjugated with the -133 bp IL-8 promoter per 
manufacturer instructions. Following wash, protein that bound the IL-8 promoter 
conjugated to µMACS beads were eluted. The total eluate was run on a 4-20% SDS-
PAGE and probed sequentially with antibodies to c-Jun, Fra-1, and Fra-2. An aliquot of 
the flow through from the µMACS beads for each sample, representative of unbound 
protein, was run separately and probed for actin (bottom) as a loading control. 
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Summary of Aim 2 
This second aim sought to characterize the activation of transcription factors 
within the IL-8 promoter by DENV proteins addressing the following questions and 
finding these answers: 
What individual transcription factors are activated by DENV proteins? 
We found that prM-E, NS1G, as well as NS5, all proteins that activate the IL-8 
promoter, also activated transcription from an AP-1 mediated reporter. In addition, we 
saw trends towards dose-dependent activation of an AP-1-mediated luciferase reporter 
with C and NS4B. Activation of the C/EBP- and NF-κB-mediated reporters were both 
very low, but by less stringent statistical analysis, we observed significant activation from 
a C/EBP-mediated reporter was induced by C, prM, E, prM-E, as well as NS5 and from a 
NF-κB-mediated reporter induced by C, E, prM-E, NS1G, and NS5. 
Does activation of the IL-8 promoter by DENV proteins depend on any single 
transcription factor? 
We found that IL-8 promoter activation by prM-E, NS1G, NS4B, as well as NS5 
did not depend on any single transcription factor. 
What components of AP-1 are activated during DENV infection? 
We found no differential activation of AP-1 subcomponents c-Jun, Fra-1, and Fra-
2 bound to the IL-8 promoter as compared to mock infected cells.
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CHAPTER IV: DISCUSSION 
 
A. Summary 
This study extends previous work from our lab and others examining the 
induction of IL-8 by DENV and DENV proteins (Medin et al., 2005; Pryor et al., 2007; 
Rawlinson et al., 2009; Li et al., 2010; Kelley et al., 2011).  Specifically, we show that 
expression of DENV-2 prM-E, NS1G, and NS4B activate the IL-8 promoter in addition 
to NS5, which we previously reported (Figure III-3B).  As we have previously reported 
for NS5, prM-E and NS1G activated AP-1-driven luciferase expression in a dose-
dependent fashion while NS4B showed a trend towards increasing luciferase expression 
with increasing dosage (Figure III-13A). Activation of the IL-8 promoter by prM-E, 
NS1G, NS4B and NS5 did not depend on any single transcription factor (Figure III-14). 
This evidence supports the hypothesis that multiple DENV proteins drive IL-8 
expression, potentially explaining the dramatic induction of IL-8 mRNA production 
during viral infection and the collective observations of induced IL-8 secretion after 
infection of multiple cell types. 
It was previously reported that NS5 is the only protein that induces IL-8 secretion 
(Medin et al., 2005). In this work, we were unable to confirm IL-8 secretion after 
transfection with NS5 (Figure III-8C). This may be due to differences in transfection 
efficiency and transfection reagents (Figure III-5A), as we observed high background 
with the negative plasmid control (Figure III-8C and Figure III-12). Perhaps due to this 
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high background, we did not observe any significant differences in IL-8 secretion as 
compared to the negative control.  
We also further analyzed DENV NS5-mediated cytokine induction. NS5 
additionally activated the RANTES promoter (Figure III-9) and TNFα mRNA production 
(Figure III-10A). However, we were unable to detect TNFα secretion (Figure III-10B). 
TNFα is associated with DHF and RANTES is secreted after infection of a variety of cell 
types. The activation of these two cytokines correlates with the common usage of AP-1 
and NF-κB between all promoters for IL-8, RANTES, and TNFα. Other inflammatory 
cytokines regulated by combinations of AP-1, C/EBP, or NF-κB that are important to 
DENV infection include IL-1 and IL-6, both of which are secreted from DENV infected 
macrophages and mast cells.  
In addition, we found that the polymerase domain, but not polymerase function, 
was required for NS5-mediated IL-8 secretion (Figure III-12). Together, this corroborates 
findings that mutations within a small region of the polymerase domain correlate with 
DENV NO induction and sensitivity, as well as IL-6 and IL-8 secretion from THP-1 cells 
(Ubol, Chareonsirisuthigul, et al., 2008). 
 Collectively, these results support a model of multiple mechanisms of IL-8 
promoter activation by DENV. These results parallel reports that multiple proteins 
interfere with IFN signaling (Muñoz-Jordan et al., 2003; Ashour et al., 2009) and suggest 
that IL-8 induction is much more important to DENV infection than previously thought. 
Further, our results suggest AP-1 may be important to IL-8 activation, though AP-1 may 
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be having a modulating rather than a strictly activating effect, consistent with the 
proposal by Pryor et al. (2007) that DENV modulates IL-8 induction.  
The timing of activation of the IL-8 promoter by individual DENV proteins was 
earlier than activation of the IL-8 promoter during DENV infection. We observed a low 
level of IL-8 mRNA produced at 48 hours during DENV infection (Figure III-1D), while 
IL-8 mRNA was produced by 24 hours post-transfection with NS5 (Figure III-8B). IL-8 
promoter activation showed a parallel pattern. DENV-mediated IL-8 promoter activation 
was not detected until 72 hours post-infection (Figure III-1B), while prM-E, NS1G, 
NS4B, and NS5 induced IL-8 promoter activation was at 24 hours post-transfection 
(Figure III-3). While this may reflect differences in expression due to infection as 
compared to transfection, it also remains possible that prM-E, NS1G, NS4B, and NS5 
share similar methods of negative regulation to delay activation of the IL-8 promoter 
during DENV infection. Of note, a greater percentage of cells are infected with DENV at 
an MOI of 1 than transfected with NS5 (Figure III-1A compared with Figure III-7). If 
activation of the IL-8 promoter were based on levels of protein expression alone, 
infection would be anticipated to induce the IL-8 promoter earlier. This supports a model 
of negative regulation delaying IL-8 promoter activation during DENV infection. 
Regulation of IL-8 secretion by NS5 has already been proposed (Pryor et al., 
2007). During viral infection, hyperphosphorylation of NS5 leads to dissociation of NS5 
from NS3 and the replication complex exposing the NLS and allowing NS5 to translocate 
into the nucleus (Kapoor et al., 1995). We initially speculated (Medin et al., 2005) that 
the discrepancy in timing of IL-8 induction was related to the delayed nuclear 
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localization of NS5 in DENV-infected cells versus NS5-transfected cells. Subsequent 
generation of DENV with the NS5 NLSs mutated demonstrated that, in the absence of 
nuclear localization, there was decreased viral production but increased IL-8 secretion 
(Pryor et al., 2007). This led the authors to the hypothesis that nuclear localization may 
sequester NS5 in the nucleus in order to regulate induction of IL-8. Further analysis 
revealed that NS5 contains a nuclear export sequence and is exported from the nucleus in 
a CRM1-dependent mechanism (Rawlinson et al., 2009). Chemical inhibition of nuclear 
export led to increased virus production and decreased IL-8 secretion, supporting a model 
of cytoplasmic NS5 inducing IL-8 rather than nuclear NS5. However, the role of NS5 in 
the nucleus and the influence of IL-8 on infection are still not clear. As the authors 
propose, cytoplasmic NS5 may be mediating both transcriptional and post-transcriptional 
regulation of IL-8. Alternatively, nuclear NS5 may be activating the IL-8 promoter and, 
separately, cytoplasmic NS5 may be positively influencing IL-8 post-transcriptional 
regulation. The latter is still consistent with the reduced, but not abrogated, IL-8 secretion 
when CRM1-dependent nuclear export is chemically inhibited (Rawlinson et al., 2009).  
 DENV regulation of IL-8, as previously proposed (Pryor et al., 2007), may be one 
explanation for the increased activation of the IL-8 promoter when the AP-1 site is 
mutated. The activation of AP-1 by all DENV proteins that activated the IL-8 promoter 
was particularly striking (Figure III-13A); therefore it was surprising that mutation of the 
IL-8 promoter at the AP-1 binding site led to increased reporter gene expression (Figure 
III-14A). Similar results were reported by Gray and Pestka (2007) with these same 
mutated IL-8 reporter plasmids. In that report, they used LPS to induce IL-8. Using 
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PROMO, a web based transcription factor binding site predictor, they concluded that the 
mutation in the AP-1 site of the IL-8 promoter had generated a binding site for the 
constitutive transcription factor TFIIB.  However, repeating their analysis only identified 
a TFIIB binding site when all species, rather than Homo sapiens specifically, were 
selected, suggesting that the TFIIB binding site was not specific to humans. However, as 
human TFIIB is closely related to the TFIIB from other species (Matys, 2003), it is still 
possible that human TFIIB may bind and activate the IL-8 promoter mutated at the AP-1 
binding site. We additionally used transcription factor binding site prediction software 
TFSEARCH, TFBIND and JASPAR, each of which reported the generation of GATA-1 
or GATA-2 binding sites, but not TFIIB. 
 The analysis of components of AP-1 did not reveal any differential binding of the 
inhibitory subunits Fra-1 and Fra-2 (Figure III-16). It still remains possible that inhibitory 
AP-1 heterodimers are induced by expression of DENV proteins through the 
incorporation of the AP-1 subunit c-Fos.  While c-Fos may either inhibit or activate 
transcription AP-1-mediated transcription (Yuan et al., 2009), the conditions leading to 
inhibition or activation are not clear. Ceballos-Olvera et al. (2010) observed early 
activation of c-Jun by DENV infection. In that study, the authors reported nuclear 
localization of c-Jun within 30 minutes after DENV infection and JNK phosphorylation. 
JNK phosphorylation did not require replication competent virus; only viral binding to 
the cell surface. If c-Jun and AP-1, with the ability to bind and activate the IL-8 
promoter, are activated early in DENV infection, why is IL-8 transcription not observed 
until three days post-infection? The results of our transcription factor analysis suggest 
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that, in our HEK293A system, viral binding does not induce c-Jun dimers that can bind 
and activate the IL-8 promoter (Figure III-16). We have not confirmed whether nuclear c-
Jun is present, but the setup of the FactorFinder kit eliminates the possibility that active c-
Jun cannot bind due to inaccessibility of the IL-8 promoter. Thus, we now question 
whether c-Jun is activated at all by viral binding in our system. 
 Of note, transfection with a DENV-2 NGC replicon (Pang, Zhang, and Dayton, 
2001a), lacking M and E but still expressing C, resulted in activation of the IL-8 
promoter within 24 hours post-transfection, though at decreased levels as compared to 
transfection with NS5 alone (Medin et al., 2005 and data not shown). Transfection 
efficiency of the DENV replicon is presumed to be less than that of NS5 alone, based on 
both the plasmid size (Figure III-6) and the initial report characterizing the DENV-2 
replicon (Pang, Zhang, and Dayton, 2001a). Decreased transfection efficiency could 
account for the decreased activation of the IL-8 promoter (Medin et al., 2005). 
Alternatively, NS5 accumulation in the absence of the replication complex may activate 
the IL-8 promoter earlier, leading to the increased signal. However, early (24 hour) 
activation of the IL-8 promoter by the DENV replicon as compared to late (48 – 72 hour) 
activation of the IL-8 promoter by DENV infection suggests that activation of IL-8 by 
DENV is not only tied to individual proteins in the replication complex, but possibly new 
virus production. Possible mechanisms for these observations are discussed further in the 
next section. 
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B. Possible mechanisms of IL-8 induction by DENV 
Several theories of how DENV induces IL-8 have been proposed based on studies 
performed in multiple cell types with varying strains of DENV-2.  This work 
demonstrates that multiple DENV-2 proteins activate the IL-8 promoter (Figure III-3), 
providing further evidence that DENV may have multiple mechanisms to induce IL-8 
production and secretion. 
Direct induction of IL-8 by DENV 
 TLR-3-mediated activation of IL-8 secretion in both HEK293 cells stably 
expressing TLR-3 and the monocytic cell line U937 has been shown (Tsai et al., 2009).  
The timing of activation in these cells is important. Tsai et al. present data that at 24 
hours, IL-8 secretion is not activated in HEK293 cells by viral infection.  This is 
consistent with our data demonstrating that induction of IL-8 by DENV does not occur 
until 72 hours post infection. However, in the presence of TLR-3, TLR-7, or TLR-8, IL-8 
is secreted within 24 hours post-infection (Tsai et al., 2009). As HEK293 and HEK293A 
cells do not contain TLRs, our data, as well as others (Huang et al., 2000; Bosch et al., 
2002; Medin et al., 2005; Medin and Rothman, 2006; Pryor et al., 2006; Rawlinson et al., 
2009; Li et al., 2010) demonstrate that TLR-3 is not the only mechanism that activates 
IL-8. Our study both extends the observation that IL-8 secretion may be induced after 
infection of cells that do not contain TLR-3, and offers a potential explanation for the 
diversity of cell types that produce IL-8 after DENV infection. 
However, mast cells have been characterized as expressing TLR-3 and responding 
to the dsRNA mimic polyinosine-polycytidylic acid (polyI:C) as well as infection with 
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RSV with IFNα production (Kulka et al., 2004). Thus, one would predict based on the 
findings by Tsai et al., 2009, that mast cells would secrete IL-8 early in response to 
DENV infection. In a study of DENV-infected mast-basophil cell lines, secretion of 
RANTES, MIP-1α, and MIP-1β were observed, but not IL-8 (King et al., 2002).  This 
study used DENV-2 strain 16681 propagated in the African green monkey kidney Vero 
cell line.  As the authors did not examine IL-8 secretion from other cell lines they studied, 
such as U937, which have clearly been shown to secrete IL-8 in response to DENV 
infection, it is difficult to determine whether the absence of IL-8 is general to mast cells, 
specific to this mast-basophil cell line, or due to the strain and/or propagation method of 
DENV-2 used in that study. Overall, IL-8 secretion has been generally observed in most 
infected cells. 
 Consistent with the diverse cell types that secrete IL-8 after DENV infection, a 
direct activation of IL-8 by the DENV C protein has been demonstrated. C mediated IL-8 
activation through direct interaction with P-TEFb and binding of the -121/+61 region of 
the IL-8 promoter (Li et al., 2010).  P-TEFb is composed of CDK9 and cyclin T1 and 
enhances IL-8 production by enhancing RNA polymerase II processivity (Reviewed in 
Peterlin and Price, 2006; Saunders et al., 2006).  Specifically, P-TEFb was shown to 
associate with NF-κB as well as the AP-1 subunit c-Fos to promote transcription 
elongation of similarly regulated genes such as IL-8 (Li et al., 2010).  The authors used 
the liver cell line Huh7 as well as the epithelial HeLa cell line. We have observed NS1G- 
and NS5-mediated activation of IL-8 transcription in both HeLa cells (Figure III-4). Our 
results in HEK293A trend towards dose-dependent activation of IL-8 transcription by C, 
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but this was not statistically significant. However, the +61 bp of IL-8, not included in our 
luciferase reporter construct, may be required for P-TEFb recruitment and activity. Thus, 
the lack of IL-8 promoter activation by C is not altogether unexpected. However, the 
activation of P-TEFb by the DENV C protein or direct binding of nuclear C to the IL-8 
promoter during replicon transfection or DENV infection could potentially enhance the 
transcriptional activation of IL-8 by AP-1 and NF-κB induced by NS1G and NS5 in these 
cell lines. In our study, the trend toward IL-8 promoter activation and AP-1-driven 
luciferase expression could be explained if low level activation of P-TEFb in HEK293A 
cells was occurring. However, it is also possible that activation of P-TEFb is only a 
property of the DENV-2 strain PL046 used by Li et al. An earlier study with HUVEC 
cells did show induction of IL-8 secretion with what may be the same strain (PL0046 
versus PL046), though to a lower level than DENV-2 strain 16681 (Huang et al., 2000). 
 Yet Li et al. (2010) also observed association of C with the IL-8 promoter by 
chromosome immune-precipitation assay, indicating direct binding. Indeed, direct 
binding of C to nuclear DNA has also been shown in the Huh7 cell line with DENV-2 
NGC (Colpitts et al., 2011). In that study, C was characterized as a histone mimic, 
dimerizing with core histones H2A, H2B, H3, and H4, disrupting oligomerization and 
post-translational modification of those histones without disrupting DNA binding. 
Alteration of chromosome structure is another well-established mechanism of gene 
regulation. Thus the trend towards IL-8 promoter (Figure III-3) and AP-1-mediated 
promoter activation (Figure III-13A) that we observed in the presence of C may reflect 
changes in chromosome structure that open up the gene for further transcription.  In the 
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context of viral infection, C-mediated chromosome alterations could partly explain the 
greatly enhanced IL-8 mRNA production as compared to transfection with individual 
DENV constructs, as C may open and “prime” the IL-8 promoter for prM-E-, NS1G-, 
NS4B- and NS5-mediated activation. 
We found that expression of the NS5 protein of DENV-2 strain NGC induced 
TNFα mRNA as well as IL-8 mRNA (Figure III-10A).  ER stress is a possible 
mechanism of IL-8 activation (Park et al., 2010), but this link has not been studied 
directly.  However, a study comparing a representative strain from each DENV serotype 
found that all induced ER stress and TNFα mRNA, though to varying levels, within U937 
cells (Klomporn et al., 2011). Whether induction of ER stress caused or only correlated 
with TNFα mRNA production is not clear from this study. 
Extracellular signaling and lipid rafts 
Previously, it has been reported that DENV induces JNK and p38 activation 
through lipid rafts (Ceballos-Olvera et al., 2010). This activation did not require 
replication competent virus and was disrupted by the depletion of cholesterol. This study 
was performed in primary monocyte-derived macrophages with DENV-2 strain 16681 
passaged in suckling mice brains. Results using replication deficient DENV produced by 
UV inactivation suggests receptor binding or uptake of virions as a mechanism of AP-1 
activation (Ceballos-Olvera et al., 2010). This correlates with our results with prM-E 
(Figure III-13A). Co-expression of the structural proteins prM and E of DENV has 
previously been shown to produce low levels of VLPs; virions that lack vRNA (Purdy 
and Chang, 2005). We were unable to confirm VLP formation from our prM-E-
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expressing plasmid, though it remains possible that VLP or virion secretion and binding 
on the outside of cells activates AP-1 and IL-8. E has been characterized to bind, activate 
several cell surface receptors, and initiate intracellular signaling. This appears to play 
diverse roles outside the context of infection, such as binding and activation of the 
NKp44 receptor of NK cells (Hershkovitz et al., 2009). E produced without prM is 
retained in the ER (Hsieh et al., 2008). If E binding to an extracellular receptor was 
inducing IL-8 in our system, then, the presence of prM would be required to form VLPs 
and transport E outside the cell. This model correlates with our observation that AP-1 is 
only induced by prM-E and not with prM or E separately, nor prM + E. However, it is 
also possible that viral protein production or processing is responsible for the activation 
of AP-1 and IL-8 that we observed. 
While neither IL-8 activation nor the possible role of NS proteins in JNK 
activation were measured in this study, the dependence of JNK activation on cholesterol 
(Ceballos-Olvera et al., 2010) suggests a possible mechanism of AP-1 and IL-8 activation 
by NS1G. NS1G has been shown to associate with lipid rafts (Noisakran et al., 2008), 
and GPI-linked proteins are well established to induce signaling after localization and 
clustering within lipid rafts (Sharom and Lehto, 2002). A possible reason that we 
observed signaling in the absence of antibody, whereas the original study characterizing 
this form of GPI-linked NS1 required antibody (Jacobs et al., 2000) may simply be due to 
overexpression within our system. NS1G is expressed at very low levels during viral 
infection (Jacobs et al., 2000), and thus requires antibody to induce clustering required to 
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activate signaling, while overexpression and localization to lipid rafts may induce 
signaling in the absence of antibody.  
NS1G, has not been well studied. In the original work that characterized it, NS1G 
was found to be expressed at very low levels during infection and was capable of 
signaling in the presence of anti-NS1 antibody as determined by general tyrosine 
phosphorylation (Jacobs et al., 2000).  The tyrosine phosphorylation profile was similar 
to that of CD55 (decay acceleration factor; DAF), another GPI-linked protein and 
suggests the involvement of sarcoma (Src) family kinases such as lymphocyte-specific 
protein tyrosine kinase (LCK), LCK/Yamaguchi sarcoma (Yes)-related novel protein 
tyrosine kinase (LYN) and FYN. These proteins are involved in a number of cellular 
processes ranging from actin reorganization and calcium signaling in general to diverse 
specific functions such as TCR signaling (DAF) (Sharom and Lehto, 2002), mast cell 
degranulation (LYN) (Alvarez-Errico et al., 2010), and NK cell signaling (FYN) (Bloch-
Queyrat et al., 2005). It remains unclear whether any or all of these signaling pathways 
are involved in mediation of IL-8 promoter activation after DENV infection. However, 
other systems have linked src tyrosine kinase signaling to IL-8 and AP-1/NF-κB 
activation (Cannon and Cesarman, 2004; Kim et al., 2004). 
To test whether the GPI linkage was required for activation of the IL-8 promoter 
by NS1G, we treated cells with increasing concentrations of phosphoinisitol-dependent 
phospholipase C (PI-PLC), an enzyme that specifically cleaves the GPI linkage from 
attached proteins (Sharom and Lehto, 2002). Our results were inconclusive (data not 
shown), most likely due to the lack of available cell culture purified PI-PLC.  Therefore, 
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it also remains possible that protein production within the ER or another intracellular, 
rather than extracellular signal induces AP-1 activation and IL-8 promoter activation. 
DENV is not the only flavivirus to express an alternative form of NS1.  Recently, 
viruses of the JE serogroup have been shown to produce an alternative form of NS1 
through ribosomal frameshift.  This alternative form is designated NS1’ and may play a 
role in neuroinvasiveness of JEV and WNV (Firth and Atkins, 2009; Melian et al., 2010). 
Whether NS1’ and NS1G are related remains to be determined, however it does suggest 
that alternative forms of NS1 may play an important conserved role in the flavivirus 
lifecycle. The role in signaling of NS1G may only be one important role given the 
multifunctional nature of flavivirus proteins. 
Soluble mediators of IL-8 induction 
While direct induction of IL-8 is strongly indicated by our work, we have not 
eliminated the possibility that another soluble factor produced early after individual 
DENV protein expression mediates activation of the IL-8 promoter.  However, 24 hours 
is early for a model of DENV protein expression, activation of an unidentified soluble 
mediator, receptor-mediated signaling of IL-8 promoter activation, and subsequent 
luciferase expression. We did find that TNFα mRNA was increased after transfection 
with an NS5-expressing plasmid (Figure III-10A). The expression and secretion of TNFα 
could activate IL-8 through the TNFα receptor (TNFR). However, we were not able to 
confirm TNFα protein expression (Figure III-10B), consistent with the substantial post-
transcriptional regulation of TNFα mRNA. 
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Another soluble mediator of inflammation that induces IL-8 is NO. In a clinical 
study, NO was reported to be elevated during DF, yet during DHF, NO levels were 
comparable to healthy controls (Valero et al., 2002). Charnsilpa et al. (2005) reported that 
24 out of 40 clinical isolates of DENV-2 were sensitive to NO. The inhibition was found 
to be in vRNA replication (Charnsilpa et al., 2005; Takhampunya et al., 2006), 
suggesting NS5 or the replication complex to be the targets of NO-mediated antiviral 
effects. It was subsequently reported that NO sensitivity was dependent on the DENV-2 
strain in a study that compared the sequences of NO sensitive and NO resistant DENV-2 
clinical isolates (Ubol, Chareonsirisuthigul, et al., 2008). Again, NS5 was implicated as a 
possible determinant of NO sensitivity. While this study used 5 DENV-2 strains from DF 
patients that were susceptible to NO and 5 DENV-2 strains that were resistant from DHF 
patients, it remains unclear whether NO resistance correlates with DHF.  Interestingly, 
NO resistant strains also showed increased NO secretion in THP-1 cells. Correlating with 
increased NO secretion, induction of IL-8 mRNA was 13-fold greater in THP-1 cells 
infected with NO resistant strain than a NO susceptible strain.  However, while increased 
levels of IL-8 in patients correlates with disease severity, the ability of clinical isolates to 
induce IL-8 secretion has not been compared. 
The role of NO during severe infection and secondary DENV infection in 
particular remains controversial. During secondary infection, NS5 may not be the only 
factor inducing NO. Antibodies to NS1 generated in mice were shown to induce 
apoptosis of the human endothelial cell line HMEC-1 via induction of NO (Lin et al., 
2002). Whether human antibodies to NS1 contribute to severe dengue remains to be seen, 
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but appears unlikely as plasma leakage without endothelial cell damage is the hallmark of 
DHF. Likewise, along with the data indicating reduced NO in DHF patients (Valero et 
al., 2002), it has been reported that DENV infection via ADE suppresses NO production, 
at least in the monocytic THP-1 cell line (Chareonsirisuthigul et al., 2007). Therefore, 
while NO production may enhance IL-8 production, NO may not be contributing to the 
increased IL-8 observed in patients during severe dengue. 
Unfolded protein response induced IL-8 
Alteration of host-cell organelles and normal processes by DENV infection has 
the potential to trigger signaling pathways resulting in downstream induction of IL-8. The 
activation of the unfolded protein response (UPR) has been noted in several studies to be 
induced by DENV (Yu et al., 2006; Umareddy et al., 2007; Paradkar et al., 2011; Peña 
and Harris, 2011) and is likely to be one mechanism of IL-8 induction. UPR has been 
associated with upregulation of mRNA transcripts of proangiogenic factors including IL-
8 (Pereira et al., 2010). While the exact mechanism of IL-8 transcript upregulation was 
not determined, it was found that upregulation of VEGF transcripts by the UPR was 
predominantly dependent on increased mRNA transcript stability rather than 
transcriptional regulation. The increased  upregulation of IL-8 (30 – 50 fold) as compared 
to VEGF (2.5 – 40 fold), depending on cell type (Pereira et al., 2010), suggests there may 
be a combination of both transcriptional and post-transcriptional upregulation of IL-8 
during UPR. Thus, activation of the UPR is one potential mechanism of DENV-induced 
IL-8 promoter activation or secretion. 
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C. Evaluation of 293A model of infection 
Here, we’ve shown that multiple DENV proteins activate transcription from the 
IL-8 promoter in HEK293A cells. This study further demonstrates several advantages of 
using HEK293A cells to study DENV infection. 
HEK293A cells are a subclone of HEK293. The parental HEK293 cell line was 
established by transformation of primary human embryonic kidney cells with sheared 
human adenovirus type 5 (Graham et al., 1977; Harrison et al., 1977). HEK293A cells, 
like the parental HEK293, express adenovirus E1a and E1b genes, tend towards 
polyploidy and contain a novel vitronectin receptor (Graham et al., 1977; Bodary and 
McLean, 1990). The E1a and E1b genes used to transform HEK293 cells must modify 
gene expression, representing another potential disadvantage to using these cells. 
HEK293 cells are also TLR deficient (Schwandner et al., 1999; Lien et al., 2001; 
Matsumoto et al., 2002), eliminating one of the major pathways of NF-κB-mediated IL-8 
transcription, known to play a role in DENV infection (Tsai et al., 2009). The absence of 
TLRs highlights additional pathways that must play a role in the activation of IL-8 
transcription.  
The question remains of how representative this model is of clinical infection. 
This is a general problem with all DENV models, but must be further questioned using 
cell lines in particular. This is not only a question of how significant observed 
phenomena are to pathogenesis, but also whether characterized phenotypes actually occur 
during clinical infection. One study in particular that highlights this problem examined 
NS5-mediated inhibition of STAT2 signaling (Ashour et al., 2009). The authors found 
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that NS5, when expressed alone, bound to STAT2.  However, when amino-terminally 
cleaved by the NS2B-NS3 protease, NS5 not only bound, but also degraded STAT2, 
leading to the observed inhibition. This result demonstrates that the context of expression 
of individual DENV proteins can have a substantial impact on protein function. 
Within our study, the importance of context is demonstrated by a comparison of 
Figure III-1B and Figure III-3. Infection with whole virus (Figure III-1B) did not activate 
substantial IL-8 transcription until 3 days post infection. However, transfection with 
prME, NS1G, NS4B and NS5 (Figure III-3) all activated the IL-8 promoter within 24 
hours. This can be further highlighted in our study by the observation that prM and E 
separately induced neither IL-8 nor AP-1 yet the prM-E construct induced both IL-8 and 
AP-1 (Figure III-3 and Figure III-13A). Kelley et al. (2011) saw a similar phenomenon in 
the monocytic U937 cell line. NS2B-NS3-mediated cleavage of the 2K sequence 
enhanced NS4B-mediated IL-8 induction. Thus, in the context of the polyprotein, 
individual proteins may induce more or less activation of the IL-8 promoter than is 
observed by expressing any single protein by itself, regardless of the cell line used for 
study. 
The first study from our group found that IL-8 was secreted only after transfection 
with an NS5-expressing plasmid (Medin et al., 2005). That study went on to further 
characterize NS5-mediated activation of IL-8 transcription. During our study, we 
measured IL-8 and TNFα protein secretion by ELISA, but saw no significant difference 
in IL-8 secretion (Figure III-8C) and no secretion of TNFα in cells transfected with 
DENV proteins (Figure III-10B). Differences in IL-8 secretion may be due to differences 
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in transfection reagents and transfection efficiencies. One possibility is that increased 
transfection efficiency led to increased background IL-8 secretion (Figure III-5). Another 
possibility is that the previously observed IL-8 secretion was through a soluble mediator 
(above) and that increased transfection efficiency of NS5 modulates induction of IL-8 
secretion, as first proposed in Pryor et al. (2007). Neither of these possibilities detracts 
from our previous study and the conclusion that DENV NS5 induces IL-8 (Medin et al., 
2005). These explanations do provide possible further insight into the mechanism of 
DENV induced IL-8. 
We have found HEK293A cells particularly useful in our studies for examining 
IL-8 promoter activation by luciferase assay. HEK293A cells are easily infected by 
DENV-2 NGC, yielding clear, consistent responses to infection. While HEK293 cells are 
kidney derived and the kidney has not been demonstrated to be a target of DENV 
infection, analysis of infection efficiency demonstrated 16% infection with an MOI of 1 
and a maximum of 90% infection with an MOI of 20 as measured by staining with the 
anti-E monoclonal antibody 3h5 and subsequent flow cytometry (Figure III-1A). In 
addition, epithelial cells are not considered as clinically relevant to infection as 
monocytic cell lines such as THP-1, U937, and K562. However, HEK293A cell are fast 
growing, have excellent transfection efficiency in general, and are efficiently transfected 
by lipid based transfection reagents, ideal for transfection-dependent assays such as our 
luciferase assay. High transfection efficiency is the reason we switched from the liver cell 
line HepG2 to studying IL-8 in HEK293A (Medin et al., 2005). Thus, while HEK293A 
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cells may be less clinically relevant than other cell lines, the high transfection efficiency 
is a distinct advantage to using this cell line. 
Overall, HEK293A cells provide a balance with being derived from a primary 
human cell, having high transfection efficiency, high expression of IL-8 and low but 
potential clinical relevance. 
D. IL-8 as a regulatory model of other cytokines 
There are disadvantages to studying IL-8. First, IL-8 does not exist within mice. 
The closest murine homologue is growth-regulated-α (GRO-α or CXCL1), which is even 
more closely related to human GRO-α (CXCL1) and has its own distinct regulation and 
roles in inflammation and immune function. As such, the downstream effects of IL-8 
must be inferred from human studies and cell culture models and there is little 
opportunity for systemic manipulation. Second, IL-8 can be induced by transfection as 
well as shear stress on cells (Lund et al., 2010; Dolan et al., 2011; Zeng et al., 2011), 
giving IL-8 a relatively higher baseline induction in some cell types. The luciferase assay 
internally controls for potential IL-8 promoter activation caused by transfection, as the 
basal one fold induction is pcDNA transfection. 
However, the study of IL-8 induction by DENV also provides a number of 
advantages over studying other cytokines. First, IL-8 is secreted by a number of cells, 
including many cell culture models, allowing for extensive observation in different cell 
types. Second, the promoter of IL-8 is relatively simple and well characterized, as 
transcription is predominantly governed by only three well studied transcription factors 
(Mukaida, 2000). As such, specific promoter mutations that abrogate binding of single 
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transcription factors are reliable means to determine the dependence of the promoter on 
any single transcription factor. Lastly, the post-transcriptional regulation of IL-8 is also 
relatively simple as compared to other cytokines such as TNFα (Eulalio et al., 2007). 
Post-transcriptional regulation appears to be mediated predominantly by KSRP, regulated 
by p38-induced dissociation, at a single ARE, though the binding of TTP (Balakathiresan 
et al., 2009) or HuR (Nabors et al., 2001) may also play a role. Similarly, the binding and 
retention of IL-8 protein by vWF has only been observed in endothelial cells (Romani de 
Wit, 2003; Bierings et al., 2007). Yet other inflammatory mediators contain one or more 
of these transcriptional or post-transcriptional regulatory mechanisms. As such, IL-8 is an 
excellent model to examine the induction and regulation of inflammatory cytokines by 
DENV infection. 
In our previous study, we mentioned the potential that cross interactions between 
subcomponents of transcription factors could account for differences in responses to anti-
inflammatory pharmaceuticals (Medin and Rothman, 2006). While this may appear to be 
a disadvantage to studying IL-8, the simplicity of the promoter has allowed us to identify 
the AP-1 binding site as a potential key site for both activation and regulation. 
Identification of AP-1 may not have been possible in more complex promoters such as 
that of TNFα. While AP-1 is less well characterized than NF-κB in virus infection 
models, extensive data exists on activation of AP-1 and IL-8 in various cancers, including 
the induction of inhibitory subunits (Adiseshaiah et al., 2006). 
We attempted to examine post-transcriptional regulation of IL-8. Luciferase 
plasmids were obtained that constitutively transcribed luciferase with the 3’ UTR of IL-8 
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or the 3’ UTRs of the control genes β-actin or GAPDH. If DENV induced dissociation of 
KSRP, increased mRNA accumulation, and increased translation, increases in the relative 
amounts of luciferase would have been expected in cells transfected with the plasmid 
expressing the IL-8 3’ UTR-conjugated transcripts versus transcripts containing the β-
actin or GAPDH 3’UTRs. While initial experiments with the IL-8 3’ UTR demonstrated 
dose dependent induction by NS5, we were perplexed to observe increased dose 
dependent luciferase expression in response to NS5 with all 3’ UTR luciferase reporter 
plasmids (data not shown). Because the luciferase assay measures protein (luciferase) 
rather than mRNA directly, inhibition of protein degradation would also show positive 
results in our assay. Therefore, one possible explanation for this result is that NS5 
expressed alone mediates a post-translational block on protein degradation. This has been 
characterized with Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1). EBNA1 
inhibits proteasome-mediated degradation through an internal glycine-alananine repeat 
sequence that the proteasome cannot process (Levitskaya et al., 1995; Levitskaya and 
Sharipo, 1997; Zhang, 2004). NS5 expressed alone will bind STAT2, but when processed 
by the NS2B-NS3 protease, NS5 will both bind and target STAT2 for degradation 
(Ashour et al., 2009). Thus, while it is possible that NS5 interferes with the protein 
degradation pathway when expressed alone, the study of NS5-mediated STAT2 
inhibition indicates any interference is likely an artifact of expressing NS5 outside the 
context of the DENV polyprotein rather than a specific function of NS5. Further study of 
3’ UTR mediated post-transcriptional regulation of IL-8 will need to directly measure 
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mRNA with the IL-8 3’ UTR, rather than using reporter protein expression such as the 
luciferase assay. 
E. Consequences of IL-8 induction by dengue virus 
There are several possible reasons DENV uses multiple mechanisms to activate 
IL-8 production in infected cells. While IL-8 is classically characterized as a neutrophil 
chemoattractant, the CXCR1 and CXCR2 receptors are expressed on a broad number of 
monocytic cells, including all the cells proposed to be the main targets of DENV 
infection: DCs, macrophages, and mast cells.  Thus, we propose that the primary role of 
induced IL-8 secretion by DENV-infected cells may be recruitment of new target cells 
for infection. 
IL-8 also has another effect that could be aiding infection.  IL-8 induced by HCV 
reduces the effectiveness of IFNα against infection (Polyak et al., 2001). Perhaps 
coincidentally, HCV NS5A induces IL-8 and, like DENV NS5, has also been 
characterized to block the IFN response (Taguchi, 2004; Ashour et al., 2009). IL-8 
induces a positive feedback loop to induce further transcription of itself in CXCR1- and 
CXCR2-containing cells, further potentiating its downstream effects. Overall, NS5 may 
be blocking the IFN response through multiple mechanisms, with IL-8 potentiated 
through a positive feedback loop. 
Yet IL-8 may also mediate protective effects that are not necessarily 
advantageous to viral infection. Such a role was proposed by Pryor et al. (2007) based on 
a study in HCV (Koo et al., 2006). While there is no definitive intracellular antiviral role 
for IL-8 as proposed by Koo et al., IL-8 is established to mediate intercellular antiviral 
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immunity. IL-8 may induce early recruitment of NK and NKT cells (Azeredo et al., 2006; 
St John et al., 2011). DENV and WNV both activate NK cells through the NKp44 
receptor (Hershkovitz et al., 2009) while DENV NS proteins upregulate HLA type I as 
protection from lysis of infected cells by NK cells (Hershkovitz et al., 2008).  Early 
activation of NK cells is associated with mild disease (Azeredo et al., 2006) and 
antibody-dependent cellular cytotoxicity (ADCC) is thought to play a protective role 
during secondary DENV infection (Kurane et al., 1984). Current data suggest that the 
protective effects of NK cells on DENV infection are mediated by CD16
-
 NK cells 
(Yoshida et al., 2011) rather than the IL-8 responsive CD16
+
 NK cells. However, this 
observation was made in a primate model that does not take into account secondary 
infection. Therefore, it is still plausible that IL-8 recruitment and DENV activation of 
CD16
+
 NK cells, important producers of IFNγ (Robertson, 2002), may further potentiate 
IFNγ production and the CD8+ T cell response (Vankayalapati et al., 2004). 
Elevated levels of IL-8 have been recorded in DHF vs DF patients (Raghupathy et 
al., 1998). While there is greater risk of DHF during secondary infection, DHF during 
primary infection does occur. The role of IL-8 in DHF may be due to a combination of 
the following factors in primary and secondary DENV infections. During primary 
infection: 
1. Increased recruitment of DENV target cells to the site of infection. 
2. Increased cytokine secretion from IL-8-responsive cells. 
3. Early protection from the antiviral effects of IFNα.  
4. IL-8 induced vascular permeability. 
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During secondary infection, these additional factors may further potentiate the negative 
effects of IL-8 and lead to DHF: 
5. ADE, further increasing viral load and IL-8 secretion. 
6. Selective recruitment of effector memory CD8+ T cells to the site of 
infection. 
7. Increased recruitment of CD16+ NK cells and subsequent IFNγ secretion, 
activating effector CD8
+
 T cells. 
Thus, the occurrence of DHF may be based on the ability of the infecting DENV to 
induce IL-8, the susceptibility of the patient to DHF through host factors, and the patient 
history of DENV infection. 
While this study used the NGC prototype strain of DENV-2, the results presented 
here correlate with results seen in studies with DENV-2 lab genotypes 16681 (Pryor et 
al., 2007) and PL046 (Li et al., 2010). Further, current studies comparing Asian 
genotypes suggest that the ability of specific DENV-2 genotypes to induce cytokine 
secretion may correlate with resistance to induced antiviral effects and pathogenesis of 
severe disease (Ubol, Chareonsirisuthigul, et al., 2008). However, it also remains to be 
seen if IL-8 and other cytokine-inducing properties of DENV-2 translate to DENV-1, -3, 
and -4. 
F. Conclusion and future directions 
 While previous studies have demonstrated the contribution of individual proteins 
to IL-8 secretion as well as TLR3-dependent IL-8 induction (Tsai et al., 2009), this study 
examined IL-8 promoter activation in the absence of TLRs. The IL-8 promoter activation 
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induced by prM-E, NS1G, NS4B and NS5 that we describe may act synergistically, 
differentially over time, or ensure IL-8 promoter activation in multiple infected cell types. 
Our demonstration that TNFα mRNA is also induced by NS5 in HEK293A cells paired 
with the observation of secretion of IL-8 and TNFα induced by NS4B in THP-1 cells 
(Kelley et al., 2011, 2012) supports a model of cytokine induction by multiple proteins to 
ensure induction in multiple cell types (Figure IV-1). C could aid this process through 
chromatin modification (Colpitts et al., 2011) and recruitment of P-TEFb (Li et al., 2010). 
The observations that NS4B (Kelley et al., 2011) and NS5 (Medin et al., 2005) induce IL-
8 secretion suggest that NS4B and NS5 may mediate ARE-BP dissociation and post-
transcriptional regulation of IL-8. Our study also adds to others implicating NS5, and the 
polymerase domain specifically, as mediating induction of other clinically important 
inflammatory mediators (Ubol, Chareonsirisuthigul, et al., 2008). Early IL-8 production 
may recruit DCs, macrophages, and mast cells to the initial site of infection for further 
DENV infection (Figure IV-1). 
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Figure IV-1: Model of IL-8 induction by DENV proteins. 
The IL-8 induction pathway outlined in Figure I-4 is adapted here to illustrate probable 
routes of induction by individual DENV proteins. This work has illustrated that prM-E, 
NS1G, NS4B, as well as NS5 induce activation of the IL-8 promoter (Figure III-3). The 
induction AP-1, C/EBP, and NF-κB luciferase reporters by prM-E and NS5 as well as 
activation of AP-1 and NF-κB luciferase reporters by NS1G (Figure III-13) suggest the 
involvement of NF-κB, JNK, and p38 MAPK pathways, delineated by dotted lines. 
Further, activation of the IL-8 promoter by prM-E, NS1G, NS4B, and NS5 is not 
dependent on AP-1, C/EBP, or NF-κB, as indicated by our data using IL-8 promoter 
constructs mutated at AP-1, C/EBP, or NF-κB transcription factor binding sites (Figure 
III-14). IL-8 promoter activation by prM-E may be due to formation, binding, or 
receptor-mediated uptake of VLPs. IL-8 promoter activation by NS1G most likely 
requires αNS1 antibody in the context of viral infection, as indicated by (Jacobs et al., 
2000). IL-8 promoter activation by NS1G in the absence of antibody in this study is most 
likely due to the over-expression system used. We also show that NS5 can activate the 
RANTES promoter (Figure III-9) and induce TNF mRNA (Figure III-10A). This study 
further demonstrates that the polymerase domain of NS5 was sufficient, but polymerase 
function was not required, for NS5-mediated induction of IL-8 (Figure III-12). Recent 
studies have indicated that activation of IL-8 by NS5 most likely occurs in the cytoplasm 
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rather than the nucleus (Pryor et al., 2007; Rawlinson et al., 2009). Other recent studies 
have demonstrated that TLR3 induces IL-8 through NF-κB (Tsai et al., 2009) and that C 
induces IL-8 through enhanced RNA polymerase II processivity through P-TEFb (Li et 
al., 2010). This study indicates that IL-8 induction by DENV C may also be due to a non-
specific induction of IL-8 (Figure III-3), possibly related to chromatin modification by C 
(Colpitts et al., 2011). IL-8 mRNA is regulated post-transcriptionally, best characterized 
in the constitutive association of IL-8 mRNA with the ARE-BP KSRP. KSRP 
dissociation from the IL-8 ARE is induced by the MAPK p38 and leads to stabilization 
and translation. Therefore, secretion of IL-8 induced by NS5 (Medin et al., 2005) and 
NS4B (Kelley et al., 2011) is likely to activate p38 and induce subsequent IL-8 mRNA 
translation and protein secretion.   
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 There are several possible lines of future research. First and foremost, the exact 
mechanism of IL-8 induction still remains unknown. Our data supports the model of 
multiple cell type-dependent mechanisms of IL-8 induction as previously proposed 
(Medin and Rothman, 2006). Future directions for research can broadly be divided into 
cell signaling that induces IL-8, viral requirements for IL-8 induction, and the roles of IL-
8 during DENV infection. Cell signaling includes ER stress and GPI-mediated signal 
pathways, as described above, as possible starting points. Viral requirements include 
determination of DENV protein-protein interactions that regulate IL-8 induction, analysis 
of DENV protein expression in the context of the polyprotein, and further examination of 
the relevance of NS1G in the context of viral infection. Here, we have further described 
DENV-2 strain NGC-mediated induction of IL-8. Questions remain. Do other strains of 
DENV-2 that correlate with increased or decreased severe dengue have corresponding 
ability to induce IL-8? What is the capability of other DENV serotypes to induce IL-8? 
Finally, while we have proposed possible roles for IL-8 in infection, these have yet to be 
formally demonstrated. 
Cell signaling 
 The signaling pathways DENV uses to induce IL-8 remain unknown. Delineation 
of these pathways could provide potential antiviral targets or further elucidate potential 
negative interactions with current pharmaceuticals as in (Medin and Rothman, 2006). ER 
stress and subsequent induction of UPR is a possibility described above. However, the 
role of GPI linkage in signaling pathways currently has more clues about potential targets 
(see below). 
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Viral requirements for DENV-induced IL-8 
 During infection, early IL-8 induction has the potential for early recruitment and 
activation of NK cells and early IFNγ production, both associated with protection from 
severe dengue. As such, two questions that remains from this work is how and why IL-8 
induction is delayed until three days post-infection in the context of viral infection. 
Transfections with a DENV replicon (Medin et al., 2005) and results with prM-E both 
demonstrated IL-8 promoter activation 24 hours post-transfection (Figure III-3). Possible 
tests of interactions that may recapitulate a delay in IL-8 promoter activation include 
prM-E cotransfected with the DENV replicon, a C-prM-E construct, or trans-
complementation of prM-E with other DENV proteins. Recapitulation of the delay in 
DENV induced IL-8 and examination of the transcription factors, if any, induced during 
this time could provide further insight into the underlying signaling processes. 
 Similarly, polyprotein expression and trans-complementation of IL-8-inducing 
proteins could further differentiate the mechanisms behind multiple DENV proteins 
activating the IL-8 promoter. Such a study could potentially differentiate between 
independent parallel activation of the IL-8 promoter, additive activation of the IL-8 
promoter, or synergistic activation of the IL-8 promoter. However, both our results with 
prM-E and the results of Kelley et al. (2011) studying NS4B-induced IL-8 suggest that 
expression in the context of the polyprotein could potentiate IL-8 induction in the 
absence of other factors. The exception to this is NS1G. Decreased expression would be 
expected rather than increased due to the small amounts of NS1G produced during 
DENV infection (Jacobs et al., 2000). Supplying NS1G in trans to other DENV proteins 
161 
 
that induce IL-8 could differentiate how NS1G signaling interacts or does not interact 
with signaling of other DENV proteins that induce IL-8. Alternatively, and more relevant 
to infection, the addition of anti-NS1 antibodies could induce NS1G-mediated IL-8 
promoter activation. Therefore, trans-complementation as well as the use of anti-NS1 
antibodies are both potential approaches to determining how and possibly why DENV 
proteins work together to induce IL-8. 
 This is the first work we know of linking NS1G signaling with a clinically 
relevant mediator of dengue. While not demonstrated in this work or any other in 
epithelial cells, the addition of NS1-specific antibody during viral infection has been 
shown to enhance IL-6 and IL-8 secretion from endothelial cells 24 hours post-infection 
(Lin et al., 2005). It is unclear whether induction of IL-6 and IL-8 in that system depends 
on GPI-linked NS1. Furthermore, antibodies to NS1 could potentially induce IL-8 
promoter activation and IL-8 secretion at 24 or 48 hours post infection in epithelial, 
monocytic, or hepatic cells, earlier than we observe with DENV infection alone (Figure 
III-1B). Induction of IL-8 through anti-NS1 antibody binding to NS1G could be another 
potential mechanism of enhanced cytokine secretion during secondary DENV infection. 
Our experiments involving treatment of cells with PI-PLC ultimately could not determine 
whether GPI linkage was involved in IL-8 promoter activation by NS1G. However, 
cholesterol depletion is a more established cell culture method that could reliably 
implicate GPI-mediated signaling. Likewise, inhibition of Src family kinases by chemical 
inhibition or RNA silencing could begin to delineate a definitive signaling pathway. The 
further study of NS1G is not only clearly defined, but could describe a hitherto 
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unrecognized clinical role for NS1G, mediating NS1 antibody-dependent enhancement of 
early inflammatory cytokine secretion from a variety of cell types. 
Analysis of other DENVs 
 While our study correlates with differences found with clinical isolates of DENV-
2 (Ubol, Chareonsirisuthigul, et al., 2008), a definitive comparison of the IL-8 and 
inflammatory cytokine induction by individual proteins, and NS5 in particular, from 
clinical isolates could provide further insight into the clinical significance of these 
findings. Likewise, a comparison of the IL-8 and inflammatory cytokine induction of 
individual proteins from American genotypes of DENV-2 may provide further 
explanation why these genotypes are associated with a lower incidence of DHF. 
 Our study could also be extended to other DENVs. As DENVs are four closely 
related viruses and IL-8 has been almost ubiquitously described from clinical studies that 
have examined IL-8 secretion, induction of IL-8 would be expected. A DENV-4 
infectious clone, the subsequent series of alanine mutations generated within NS5, the 
ability to generate viruses incorporating those mutations, and the data already collected 
from mouse infections with those recombinant viruses (Hanley et al., 2002) provide an 
attractive starting point for such a study. The data from the crystal structure of DENV 
NS5 polymerase derived from DENV-3 (Yap et al., 2007) paired with the alanine 
mutants of NS5 would be a powerful tool to further dissect the conservation of structures 
and function between the NS5s of different DENV serotypes. Co-IP with individual NS5s 
from DENV-2 and DENV-4 would demonstrate conserved and novel protein interactions 
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between serotypes, thus highlighting differences and similarities between these closely 
related viruses. 
Determination of downstream roles for IL-8 during dengue 
 The downstream effects of IL-8 during DENV infection have yet to be elucidated, 
but the induction of IL-8 promoter and secretion by multiple proteins suggests an 
important role in infection. Here, we suggest that IL-8 secretion could be a means of 
recruitment of CXCR-1 and/or CXCR-2-expressing targets of infection, including 
dendritic cells and macrophages. However, it remains to be determined whether target 
cells are IL-8 responsive and if DENV can infect target cells that have been treated with 
IL-8. While cytokine secretion from multiple infected cell types has been described, the 
potential changes in the ability of DENV to infect target cells pre-treated with cytokines 
such as IL-8 have been lacking. Studies in HCV suggest that an increased ability of cells 
to secrete IL-8 may be inhibitory to viral replication (Koo et al., 2006). Pretreatment of 
primary human monocyte-derived macrophages with TNFα, one inducer of IL-8, was 
demonstrated not to interfere with DENV infection or replication (Wati et al., 2007) 
suggesting that IL-8 does not have the same inhibitory effect on DENV replication. 
However, pre-treatment of potential target cells with IL-8 has not been formally tested. 
Pretreatment of cells with IFN is protects cells from DENV infection (Diamond and 
Harris, 2001). While IL-8 inhibits IFN (Polyak et al., 2001), it is unclear whether IL-8 
can prevent IFN-mediated resistance to DENV infection or restore the ability of DENV 
to infect IFN-pretreated cells. Thus, the activation of IL-8 by DENV and DENV proteins 
remains a wide area for research with potential clinical applications.  
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